Skip over navigation
Outline
Indent Level
Color Curly Brackets (indicating CPC extensions to IPC)

CPC
COOPERATIVE PATENT CLASSIFICATION
Collapse
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES( devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J 3/00 ; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L ;
{
compounds per se C01 , C07 , C08 , C12N
}
; soap compositions C11D ;
{
micro-organisms per se C12N
}
)
NOTE
-
This subclass covers the following subject matter, whether set forth as a composition (mixture), process of preparing the composition or process of treating using the composition:
Drug or other biological compositions which are capable of:
- preventing, alleviating, treating or curing abnormal or pathological conditions of the living body by such means as destroying a parasitic organism, or limiting the effect of the disease or abnormality by chemically altering the physiology of the host or parasite (biocides A01N 25/00 to A01N 65/00 );
- maintaining, increasing, decreasing, limiting, or destroying a physiological body function, e.g. vitamin compositions, sex sterilants, fertility inhibitors, growth promotors, or the like (sex sterilants for invertebrates, e.g. insects, A01N ; plant growth regulators A01N 25/00 to A01N 65/00 );
- diagnosing a physiological condition or state by an in vivo test, e.g. X-ray contrast or skin patch test compositions (measuring or testing processes involving enzymes or micro-organisms C12Q ; in vitro testing of biological material, e.g. blood, urine, G01N , e.g. G01N 33/48 )

Body treating compositions generally intended for deodorising, protecting, adorning or grooming the body, e.g. cosmetics, dentifrices, tooth filling materials.


Attention is drawn to the definitions of groups of chemical elements following the title of section C.

Attention is drawn to the notes in class C07 , for example the notes following the title of the subclass C07D , setting forth the rules for classifying organic compounds in that class, which rules are also applicable, if not otherwise indicated, to the classification of organic compounds in A61K .

In this subclass, in the absence of an indication to the contrary, classification is made in the last appropriate place.

WARNING
-
The following IPC groups are not used in the CPC scheme. Subject matter covered by these groups is classified in the following CPC groups:
A61K 6/033 covered by A61K6/06A
A61K9/133 covered by A61K 9/127
A61K9/18 covered by A61K 9/14
A61K9/22 covered by A61K 9/20
A61K9/24 covered by A61K 9/209
A61K9/26 covered by A61K 9/2077 , A61K 9/2081
A61K9/30 covered by A61K 9/28
A61K9/32 covered by A61K 9/28
A61K9/34 covered by A61K 9/28
A61K9/36 covered by A61K 9/28
A61K9/38 covered by A61K 9/28
A61K9/40 covered by A61K 9/28
A61K9/42 covered by A61K 9/28
A61K9/44 covered by A61K 9/2072
A61K9/46 covered by A61K 9/0007
A61K9/52 covered by A61K 9/50
A61K9/54 covered by A61K 9/5073 , A61K 9/5078 , A61K 9/5084
A61K9/56 covered by A61K 9/50
A61K9/58 covered by A61K 9/50
A61K9/60 covered by A61K 9/50
A61K9/62 covered by A61K 9/50
A61K9/64 covered by A61K 9/50
A61K9/66 covered by A61K 9/48
A61K9/68 covered by A61K 9/0058
A61K9/72 covered by A61K 9/0073
A61K45/08 covered by A61K 31/00 , A61K 47/00
A61K47/04 covered by A61K 47/02
A61K50/00 covered by A61K 9/0009 , C09J 9/02

The following IPC indexing codes are not used in the CPC scheme:
A61K101/00 - A61K135/00

Subgroups of A61K 48/00 are incomplete (Jan. 2003). Documents are being reclassified from A61K 48/00 to its subgroups


Collapse
Preparations for dentistry( teeth cleaning preparations A61K 8/00 , A61Q 11/00 ;
{
dental prostheses A61C 13/00 ; apparatus or methods for oral or dental hygiene A61C
}
)
NOTE
-
In groups A61K 6/00 - A61K 6/0044 and A61K 6/083 - A61K 6/10 , the use of specific polymers is indicated by addition of classification symbols of the subclass C08L preceded by the sign "+", e.g. compositions for taking dental impressions containing alginates are classified in A61K 6/10 + C08L 5/04

Collapse
.
{
Compositions characterised by physical properties
}
A61K 6/0005
. .
{
by refractive index
}
A61K 6/0008
. .
{
by particle size
}
A61K 6/0011
. .
{
by retraction, e.g. compositions for widening the sulcus for making dental impressions or removing teeth
}
A61K 6/0014
. .
{
Self-expanding, e.g. for filling teeth
}
A61K 6/0017
. .
{
Protective coating for natural or artificial teeth, such as sealing, dye coating, varnish
}
A61K 6/002
. .
{
Compositions for detecting or measuring, e.g. contact points, irregularities on natural or artificial teeth
}
Collapse
.
{
Chemical means for temporarily or permanently fixing teeth, palates or the like
}
A61K 6/0026
. .
{
Preparations for stabilising dentures in the mouth
}
.
{
Primers( adhesive primers A61K 6/0023 )
}
Collapse
.
{
Use of preparations for dental root treatment
}
A61K 6/0035
. .
{
Cleaning; Disinfecting
}
A61K 6/0038
. .
{
Filling; Sealing
}
A61K 6/0041
. .
{
Apical treatment
}
A61K 6/0044
. .
{
in combination with dental implants
}
Collapse
.
{
Preparations for dentistry characterised by the presence of organic or organo-metallic additives
}
A61K 6/005
. .
{
Cationic, anionic or redox initiators
}
A61K 6/0052
. .
{
Photochemical radical initiators
}
A61K 6/0055
. .
{
Thermal radical initiators
}
Collapse
A61K 6/0058
. .
{
Dyes
}
A61K 6/0061
. . .
{
photochromic
}
A61K 6/0064
. . .
{
thermochromic
}
A61K 6/0067
. .
{
Medicaments; Drugs
}
Collapse
.
{
Preparations for dentistry characterized by the presence of inorganic additives
}
Collapse
A61K 6/0073
. .
{
Fillers
}
A61K 6/0076
. . .
{
comprising nitrogen-containing compounds
}
A61K 6/0079
. . .
{
comprising sulfur-containing compounds
}
Collapse
A61K 6/0082
. . .
{
comprising phosphorus-containing compounds
}
A61K 6/0085
. . . .
{
Apatite
}
A61K 6/0088
. . .
{
comprising silicon-containing compounds
}
A61K 6/0091
. . .
{
Glass
}
A61K 6/0094
. .
{
Pigments
}
A61K 6/0097
. .
{
Initiators
}
Collapse
.
Use of preparations for artificial teeth, for filling or for capping teeth
Collapse
A61K 6/0205
. .
{
Ceramics
}
A61K 6/021
. . .
{
comprising manganese oxide
}
A61K 6/0215
. . .
{
comprising magnesium oxide
}
A61K 6/022
. . .
{
comprising beryllium oxide
}
A61K 6/0225
. . .
{
comprising chromium oxide
}
A61K 6/023
. . .
{
comprising iron oxide
}
A61K 6/0235
. . .
{
comprising titanium oxide
}
A61K 6/024
. . .
{
comprising zirconium oxide
}
A61K 6/0245
. . .
{
comprising hafnium oxide
}
A61K 6/025
. . .
{
comprising rare earth metal oxides
}
A61K 6/0255
. . .
{
comprising transition metal oxides
}
A61K 6/026
. . .
{
Leucite
}
A61K 6/0265
. .
{
Cermet-composites
}
Collapse
A61K 6/027
. .
Use of non-metallic elements or compounds thereof, e.g. carbon
{
( non-metallic elements per se C01B )
}
A61K 6/0273
. . .
{
Glass-ceramic-composites
}
A61K 6/0276
. . .
{
Glasses
}
A61K 6/033
. . .
{
Phosphorus compounds, e.g. apatite
}
Collapse
A61K 6/04
. .
Use of metals or alloys( alloys per se C22C )
A61K 6/043
. . .
{
Rare earth metals
}
A61K 6/046
. . .
{
Noble metals
}
A61K 6/05
. . .
Amalgams
Collapse
A61K 6/06
. .
Use of inorganic cements( cements per se C04B )
A61K 6/0606
. . .
{
Portland cements
}
A61K 6/0612
. . .
{
Silicates
}
A61K 6/0618
. . .
{
Pozzolans
}
A61K 6/0625
. . .
{
Calcium sulfates/gypsum
}
A61K 6/0631
. . .
{
Al-cements
}
A61K 6/0637
. . .
{
Ca-Al-sulfate-cements
}
A61K 6/0643
. . .
{
Phosphate cements( apatite A61K 6/033 )
}
A61K 6/065
. . .
{
Ammonium cements
}
A61K 6/0656
. . .
{
Zeolite
}
A61K 6/0662
. . .
{
Quartz or SiO2
}
A61K 6/0668
. . .
{
Carbonates
}
A61K 6/0675
. . .
{
Calcium oxide
}
A61K 6/0681
. . .
{
comprising zirconium oxide
}
A61K 6/0687
. . .
{
comprising chromium oxide
}
A61K 6/0693
. . .
{
comprising carbides
}
Collapse
A61K 6/08
. .
Use of natural or synthetic resins( resins per se C08 )
Collapse
A61K 6/083
. . .
Compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
A61K 6/0835
. . . .
{
Polycarboxylate cements or glass ionomer cements
}
Collapse
A61K 6/087
. . .
Compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
A61K 6/09
. . . .
Polyurethanes
A61K 6/093
. . . .
Polyorganosilicon compounds
A61K 6/097
. . .
Polysaccharides
.
Compositions for taking dental impressions( impression methods A61C 9/00 )
Collapse
Cosmetic or similar toilet preparations( casings or accessories for storing or handling of solid or pasty toilet or cosmetic substances A45D 40/00 )
NOTE
-
Use of cosmetics or similar toilet preparations is further classified in subclass A61Q .

1. Use of cosmetics or similar toilet preparations is mandatorily further classified in subclass A61Q . 2. In each of groups A61K 8/02 and A61K 8/18 , in the absence of an indication of the contrary, classification is made in the last appropriate place. 3. Attention is drawn to the Notes in class C07 , for example the notes following the title of subclass C07D , setting forth the rules for classifying organic compounds in that class, which rules are also applicable, if not otherwise indicated, to the classification of organic compounds in group A61K 8/00 . 4. Salts or complexes of organic compounds are classified according to the base compounds. If a complex is formed between two or more compounds, classification is made for each compound.

WARNING
-
Group A61K 8/00 and subgroups are incomplete. See provisionally also A61K7/00 and subgroups.

Collapse
.
characterised by special physical form
A61K 8/0204
. .
{
Specific forms not provided for by any of groups A61K 8/0208 to A61K 8/14
}
. .
{
Tissues; Wipes; Patches
}
. .
{
Face masks
}
Collapse
A61K 8/0216
. .
{
Solid or semisolid forms
}
Collapse
A61K 8/022
. . .
{
Powders; Compacted Powders
}
A61K 8/0225
. . . .
{
Granulated powders
}
A61K 8/0229
. . .
{
Sticks
}
Collapse
A61K 8/0233
. . .
{
Distinct layers, e.g. core/shell sticks
}
A61K 8/0237
. . . .
{
Striped compositions
}
Collapse
A61K 8/0241
. .
{
Containing particulates characterized by their shape and/or structure( see also A61K 8/04 , A61K 8/11 , and A61K 8/14 , further aspects are classified in A61K 2800/40 and subcodes )
}
A61K 8/0245
. . .
{
Specific shapes or structures not provided for by any of the groups of A61K 8/0241
}
A61K 8/025
. . .
{
Explicitly spheroidal or spherical shape
}
Collapse
A61K 8/0254
. . .
{
Platelets; Flakes
}
Collapse
A61K 8/0258
. . . .
{
Layered structure
}
A61K 8/0262
. . . . .
{
Characterized by the central layer
}
A61K 8/0266
. . . . .
{
Characterized by the sequence of layers
}
A61K 8/027
. . .
{
Fibers; Fibrils
}
A61K 8/0275
. . .
{
Containing agglomerated particulates
}
A61K 8/0279
. . .
{
Porous; Hollow
}
Collapse
A61K 8/0283
. . .
{
Matrix particles
}
A61K 8/0287
. . . .
{
the particulate containing a solid-in-solid dispersion
}
. .
{
Micelles
}
. .
{
Liquid crystals
}
A61K 8/03
. .
Liquid compositions with two or more distinct layers
Collapse
. .
Dispersions ; Emulsions
. . .
{
Gels
}
. . .
{
Suspensions
}
. . .
{
Aerosols; Foams
}
Collapse
. . .
Emulsions
A61K 8/062
. . . .
{
Oil-in-water emulsions
}
A61K 8/064
. . . .
{
Water-in-oil emulsions, e.g. Water-in-silicone emulsions
}
A61K 8/066
. . . .
{
Multiple emulsions, e.g. water-in-oil-in-water
}
. . . .
{
Microemulsions
}
. .
Encapsulated compositions
. .
Liposomes ; Vesicles
Collapse
A61K 8/18
.
characterised by the composition
Collapse
. .
containing inorganic ingredients
Collapse
A61K 8/20
. . .
Halogens ; Compounds thereof
A61K 8/21
. . . .
Fluorides ; Derivatives thereof
. . .
Peroxides ; Oxygen ; Ozone
. . .
Sulfur ; Selenium ; Tellurium ; Compounds thereof
. . .
Phosphorous ; Compounds thereof
. . .
Silicon ; Compounds thereof
. . .
Aluminium ; Compounds thereof
. . .
Zinc ; Compounds thereof
. . .
Zirconium ; Compounds thereof
. . .
Titanium ; Compounds thereof
Collapse
A61K 8/30
. .
containing organic compounds
Collapse
. . .
Hydrocarbons
. . . .
{
Halogenated hydrocarbons
}
Collapse
. . .
containing oxygen
Collapse
A61K 8/34
. . . .
Alcohols
A61K 8/342
. . . . .
{
Alcohols having more than seven atoms in an unbroken chain
}
A61K 8/345
. . . . .
{
containing more than one hydroxy group
}
A61K 8/347
. . . . .
{
Phenols
}
Collapse
A61K 8/35
. . . .
Ketones, e.g. benzophenone
. . . . .
{
Quinones
}
Collapse
A61K 8/36
. . . .
Carboxylic acids ; Salts or anhydrides thereof
A61K 8/361
. . . . .
{
Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
}
. . . . .
Polycarboxylic acids
. . . . .
Hydroxycarboxylic acids ; Ketocarboxylic acids
. . . . .
with carboxyl groups directly bound to carbon atoms or aromatic rings
Collapse
. . . .
Esters of carboxylic acids
A61K 8/375
. . . . .
{
the alcohol moiety containing more than one hydroxy group
}
A61K 8/38
. . . .
Percompounds, e.g. peracids
. . . .
Derivatives containing from 2 to 10 oxyalkylene groups
Collapse
. . .
containing nitrogen( quinones containing nitrogen A61K8/35C )
Collapse
. . . .
Amines
A61K 8/411
. . . . .
{
Aromatic amines, i.e. where the amino group is directly linked to the aromatic nucleus
}
A61K 8/413
. . . . .
{
Indoanilines; Indophenol; Indoamines
}
. . . . .
{
Aminophenols
}
A61K 8/416
. . . . .
{
Quaternary ammonium compounds( A61K 8/35 takes precedence )
}
A61K 8/418
. . . . .
{
containing nitro groups
}
. . . .
Amides
A61K 8/43
. . . .
Guanidines
Collapse
. . . .
Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur ; Salts ; Esters or N-acylated derivatives thereof
. . . . .
{
substituted by amido group(s)
}
A61K 8/445
. . . . .
{
aromatic, i.e. the carboxylic acid directly linked to the aromatic ring
}
A61K 8/447
. . . . .
{
containing sulfur
}
. . . .
Derivatives containing from 2 to 10 oxyalkylene groups
Collapse
. . .
containing sulfur( A61K 8/44 takes precedence )
A61K 8/463
. . . .
{
containing sulfuric acid derivatives, e.g. sodium lauryl sulfate
}
. . . .
{
containing sulfonic acid derivatives; Salts
}
Collapse
. . .
containing heterocyclic compounds
Collapse
. . . .
{
with one nitrogen as the only hetero atom
}
Collapse
. . . . .
{
having five membered rings, e.g. pyrrolidone carboxylic acid
}
. . . . . .
{
having condensed rings, e.g. indol
}
. . . . .
{
having six membered rings
}
. . . . .
{
having sulfur as an exocyclic substituent, e.g. pyridinethione
}
Collapse
. . . .
{
with more than one nitrogen as the only hetero atom
}
. . . . .
{
Imidazoles or their condensed derivatives, e.g. benzimidazoles
}
. . . . .
{
containing pyrimidine ring derivatives, e.g. minoxidil
}
A61K 8/496
. . . . .
{
Triazoles or their condensed derivatives, e.g. benzotriazoles
}
A61K 8/4966
. . . . .
{
Triazines or their condensed derivatives
}
Collapse
. . . .
{
with oxygen as the only hetero atom
}
. . . . .
{
having 6-membered rings or their condensed derivatives, e.g. coumarin
}
. . . .
{
with sulfur as the only hetero atom
}
. . . .
{
Derivatives containing from 2 to 10 oxyalkylene groups
}
Collapse
A61K 8/55
. . .
Phosphorus compounds
A61K 8/553
. . . .
{
Phospholipids, e.g. lecithin
}
A61K 8/556
. . . .
{
Derivatives containing from 2 to 10 oxyalkylene groups
}
Collapse
. . .
containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
. . . .
{
Organosilicon compounds
}
Collapse
. . .
Sugars ; Derivatives thereof
. . . .
{
Glycosides, e.g. rutin
}
. . . .
{
Alkylpolyglycosides; Derivatives thereof, e.g. esters
}
A61K 8/606
. . . .
{
Nucleosides; Nucleotides; Nucleic acids
}
. . . .
{
Derivatives containing from 2 to 10 oxyalkylene groups
}
A61K 8/63
. . .
Steroids ; Derivatives thereof
NOTE
-
This group covers steroids, as defined in Note (1) after the title of subclass C07J .

Collapse
. . .
Proteins ; Peptides ; Derivatives or degradation products thereof
. . . .
{
Proteins of vegetable origin; Derivatives or degradation products thereof
}
A61K 8/65
. . . .
Collagen ; Gelatin ; Keratin ; Derivatives or degradation products thereof
. . . .
Enzymes
Collapse
. . .
Vitamins
A61K 8/671
. . . .
{
Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
}
Collapse
A61K 8/673
. . . .
{
Vitamin B group
}
A61K 8/675
. . . . .
{
Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde( tocopheryl nicotinate A61K 8/678 )
}
. . . .
{
Ascorbic acid, i.e. vitamin C
}
. . . .
{
Tocopherol, i.e. vitamin E
}
. . .
Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
Collapse
. . .
containing fluorine
A61K 8/70
. . . .
containing perfluoro groups, e.g. perfluoroethers
Collapse
. .
containing organic macromolecular compounds
Collapse
. . .
Polysaccharides
A61K 8/731
. . . .
{
Cellulose; Quaternized cellulose derivatives
}
. . . .
{
Starch; Amylose; Amylopectin; Derivatives thereof
}
A61K 8/733
. . . .
{
Alginic acid; Salts thereof
}
A61K 8/735
. . . .
{
Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
}
A61K 8/736
. . . .
{
Chitin; Chitosan; Derivatives thereof
}
. . . .
{
Galactomannans, e.g. guar; Derivatives thereof
}
. . . .
{
Cyclodextrins
}
Collapse
. . .
obtained by reactions involving only carbon-to-carbon unsaturated bonds
Collapse
. . . .
{
Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Compositions of derivatives of such polymers
}
. . . . .
{
Homopolymers or copolymers of aliphatic olefines, e.g. polyethylene, polyisobutene; Compositions of derivatives of such polymers
}
. . . . .
{
Homopolymers or copolymers of aromatic olefines, e.g. polystyrene; Compositions of derivatives of such polymers
}
. . . .
{
Compositions of homopolymers or copolymers of compounds having one carbon-to-carbon double bond, and at least one being terminated by a halogen; Compositions of derivatives of such polymers, e.g. PVC, PTFE
}
. . . .
{
Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal or ketal radical; Compositions of hydrolysed polymers or esters of unsaturated alcohols with saturated carboxylic acids; Compositions of derivatives of such polymers, e.g. polyvinylmethylether
}
. . . .
{
Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an acyloxy radical of a saturated carboxylic acid, of carbonic acid or of a haloformic acid; Compositions of derivatives of such polymers, e.g. vinyl esters (polyvinylacetate)
}
Collapse
. . . .
{
Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
}
. . . . .
{
Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
}
. . . . .
{
Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers
}
. . . . .
{
Homopolymers or copolymers of amides or imides, e.g. (meth) acrylamide; Compositions of derivatives of such polymers
}
. . . .
{
Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical, and containing at least one other carboxyl radical in the molecule, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers, e.g. poly( methyl vinyl ether-co-maleic anhydride )
}
Collapse
. . . .
{
Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions or derivatives of such polymers, e.g. vinylimidazol, vinylcaprolactame, allylamines( Polyquaternium 6 )
}
A61K 8/8176
. . . . .
{
Homopolymers of N-vinyl-pyrrolidones. Compositions of derivatives of such polymers
}
A61K 8/8182
. . . . .
{
Copolymers of vinyl-pyrrolidones. Compositions of derivatives of such polymers
}
. . . .
{
Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bonds, and at least one being terminated by a bond to sulfur or by a hertocyclic ring containing sulfur; Compositions of derivatives of such polymers
}
. . . .
{
Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, at least one having two or more carbon-to-carbon double bonds; Compositions of derivatives of such polymers
}
Collapse
. . .
obained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
A61K 8/85
. . . .
Polyesters
. . . .
Polyethers
A61K 8/87
. . . .
Polyurethanes
. . . .
Polyamides
Collapse
. . . .
Polysiloxanes
Collapse
. . . . .
saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
A61K 8/892
. . . . . .
modified by a hydroxy group, e.g. dimethiconol
. . . . . .
modified by an alkoxy or aryloxy group, e.g. behenoxy dimethicone or stearoxy dimethicone
. . . . . .
modified by a polyoxyalkylene group, e.g. cetyl dimethicone copolyol
. . . . .
containing silicon bound to unsaturated aliphatic groups, e.g. vinyl dimethicone
Collapse
A61K 8/896
. . . . .
containing atoms other than silicon, carbon, oxygen and hydrogen, e.g. dimethicone copolyol phosphate
A61K 8/897
. . . . . .
containing halogen, e.g. fluorosilicones
A61K 8/898
. . . . . .
containing nitrogen, e.g. amodimethicone, trimethyl silyl amodimethicone or dimethicone propyl PG-betaine
A61K 8/899
. . . . . .
containing sulfur, e.g. sodium PG-propyldimethicone thiosulfate copolyol
A61K 8/90
. . .
Block copolymers( A61K 8/89 takes precedence )
A61K 8/91
. . .
Graft copolymers( A61K 8/89 takes precedence )
Collapse
. .
Oils, fats or waxes ; Derivatives thereof, e.g. hydrogenation products thereof
. . .
{
of vegetable origin
}
A61K 8/925
. . .
{
of animal origin
}
A61K 8/927
. . .
{
of insects, e.g. shellac
}
Collapse
A61K 8/96
. .
containing material, or derivatives thereof of undetermined constitution
. . .
{
of inanimate origin
}
Collapse
. . .
of vegetable origin, e.g. plant extracts
A61K 8/975
. . . .
{
Pollen; Algae, Higher fungi
}
Collapse
. . .
of animal origin
Collapse
A61K 8/981
. . . .
{
of mammals or bird
}
A61K 8/982
. . . . .
{
Reproductive organs; Embryos, Eggs
}
A61K 8/983
. . . . .
{
Blood, e.g. plasma
}
A61K 8/985
. . . . .
{
Skin or skin outgrowth, e.g. hair, nails
}
A61K 8/986
. . . . .
{
Milk; Derivatives thereof, e.g. butter
}
Collapse
. . . .
{
of species other than mammals or birds
}
A61K 8/988
. . . . .
{
Honey; Royal jelly, Propolis
}
. . .
from micro-organisms
Collapse
Medicinal preparations characterised by special physical form( nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparataions A61K 49/18 ; preparations containing radioactive substances A61K 51/12 )
NOTE
-
Among the one-dot groups of A61K 9/00 , classification is not made in the last appropriate place.
A61K 9/00 is subdivided according to the following concepts:
- the drug release technique ( A61K 9/0002 and subgroups),
- the site of application ( A61K 9/0012 and subgroups), and
- the physical form ( A61K 9/0087 to A61K9/70E ).
Where relevant, documents are classified in more than one of these subdivisions.

Collapse
A61K 9/0002
.
{
Galenical forms characterised by the drug release technique; Application systems commanded by energy
}
A61K 9/0004
. .
{
Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
}
A61K 9/0007
. .
{
Effervescent( A61K 9/0065 takes precedence )
}
A61K 9/0009
. .
{
involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis( microelectromechanical systems A61K 9/0097 )
}
Collapse
A61K 9/0012
.
{
Galenical forms characterised by the site of application
}
Collapse
A61K 9/0014
. .
{
Skin, i.e. galenical aspects of topical compositions( non-active ingredients are additionally classified in A61K 47/00 ; A61K 9/0009 , A61K 9/0021 , A61K 9/7015, A61K 9/7023 take precedence; cosmetic preparations A61K 8/00 , A61Q ; preparations for wound dressings or bandages A61L 26/00 )
}
A61K 9/0017
. . .
{
Non-human animal skin, e.g. pour-on, spot-on
}
Collapse
A61K 9/0019
. .
{
Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner( non-active ingredients are additionally classified in A61K 47/00 )
}
A61K 9/0021
. . .
{
Intradermal administration, e.g. through microneedle arrays, needleless injectors( mechanical aspects A61M )
}
A61K 9/0024
. . .
{
Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue( compositions for intravenous administration, normal injectable solutions or dispersions for e.g. subcutaneous administration A61K 9/0019 ; brain implants A61K 9/0085 ; (coated) prostheses, catheters or stents A61L )
}
A61K 9/0026
. . .
{
Blood substitute; Oxygen transporting formulations; Plasma extender
}
A61K 9/0029
. . .
{
Parenteral nutrition; Parenteral nutrition compositions as drug carriers
}
A61K 9/0031
. .
{
Rectum, anus
}
Collapse
A61K 9/0034
. .
{
Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
}
A61K 9/0036
. . .
{
Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
}
A61K 9/0039
. . .
{
Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
}
A61K 9/0041
. .
{
Mammary glands, e.g. breasts, udder; Intramammary administration
}
A61K 9/0043
. .
{
Nose
}
A61K 9/0046
. .
{
Ear
}
Collapse
A61K 9/0048
. .
{
Eye, e.g. artificial tears
}
A61K 9/0051
. . .
{
Ocular inserts, ocular implants
}
Collapse
A61K 9/0053
. .
{
Mouth and digestive tract, i.e. intraoral and peroral administration( rectal administration A61K 9/0031 )
}
Collapse
A61K 9/0056
. . .
{
Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
}
A61K 9/0058
. . . .
{
Chewing gums( non-medicinal aspects, preparing chewing gum A23G 4/00 ; chewing gum for care of the teeth or oral cavity, e.g. with breath freshener A61Q 11/00 )
}
A61K 9/006
. . .
{
Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
}
A61K 9/0063
. . .
{
Periodont
}
A61K 9/0065
. . .
{
Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
}
A61K 9/0068
. . .
{
Rumen, e.g. rumen bolus
}
Collapse
A61K 9/007
. .
{
Pulmonary tract; Aromatherapy
}
Collapse
A61K 9/0073
. . .
{
Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy;( nasal sprays A61K 9/0043 ; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K 9/007 ; devices A61M )
}
A61K 9/0075
. . . .
{
for inhalation via a dry powder inhaler (DPI), e.g. comprising micronized drug mixed with lactose carier particles
}
A61K 9/0078
. . . .
{
for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
}
A61K 9/008
. . . .
{
comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler (MDI)
}
A61K 9/0082
. . .
{
Lung surfactant, artificial mucus
}
A61K 9/0085
. .
{
Brain, e.g. brain implants; Spinal cord
}
Collapse
A61K 9/0087
.
{
Galenical forms not covered by A61K 9/02 to A61K 9/7023
}
A61K 9/009
. .
{
Sachets, pouches characterised by the material or function of the envelope( with gastric retention A61K 9/0065 ; sachets which are not administered but function merely as a container are classified according to the content, e.g. sachets comprising powder for reconstitution of a drink A61K 9/0095 )
}
A61K 9/0092
. .
{
Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules, nanotubes( fibres of the matrix type containing drug A61K 9/70 )
}
A61K 9/0095
. .
{
Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches( A61K 9/0007 takes precedence; eatable gels or foams A61K 9/0056 ; oral mucosa adhesive forms A61K 9/006 )
}
A61K 9/0097
. .
{
Micromachined devices; Microelectromechanical systems (MEMS); Devices obtained by lithographic treatment of silicon; Devices comprising chips( intradermal microneedle arrays A61K 9/0021 ; MEMS in general B81B 7/02 )
}
Collapse
A61K 9/02
.
Suppositories ; Bougies ; Bases therefor;
{
Ovules
}
(
{
apparatus for making A61J 3/08 ; devices for introducing into the body A61M 31/00
}
)
A61K 9/025
. .
{
characterised by shape or structure, e.g. hollow layered, coated
}
A61K 9/06
.
Ointments ; Bases therefor;
{
Other semi-solid forms, e.g. creams, sticks, gels( composition of ointments, creams or gels A61K 47/00 )
}
WARNING
-
incomplete, see also A61K 9/0012, A61K 47/00

A61K 9/08
.
Solutions;
{
( composition of solutions A61K 47/00 )
}
WARNING
-
incomplete, see also A61K 9/0012, A61K 47/00 , A61K 9/0095

Collapse
A61K 9/10
.
Dispersions ; Emulsions;
{
( A61K 9/06 takes precedence; composition of dispersions, emulsions A61K 47/00 )
}
WARNING
-
incomplete, see also A61K 9/0012, A61K 47/00 , A61K 9/0095

Collapse
A61K 9/107
. .
Emulsions;
{
Emulsion preconcentrates; Micelles( composition of emulsions A61K 47/00 )
}
WARNING
-
incomplete, see also A61K 9/0012, A61K 47/00 , A61K 9/0095

A61K 9/1075
. . .
{
Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers( A61K 9/0026 takes precedence )
}
A61K 9/113
. . .
Multiple emulsions, e.g. oil-in-water-in-oil;
{
( A61K 9/0026 takes precedence )
}
Collapse
A61K 9/12
. .
Aerosols ; Foams
{
( A61K 9/0043 , A61K 9/0056 , A61K 9/006 , A61K 9/0073 take precedence; spray-films A61K 9/7015 )
}
A61K 9/122
. . .
{
Foams; Dry foams( edible foams A61K 9/0056 )
}
A61K 9/124
. . .
{
characterised by the propellant
}
Collapse
A61K 9/127
. .
Liposomes
Collapse
A61K 9/1271
. . .
{
Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers( see also A61K 47/48815 )
}
A61K 9/1272
. . . .
{
with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids( with cholesterol as the only non-phosphatidyl surfactant A61K 9/127 ; cationic lipid/DNA complexes see also A61K 47/48046 )
}
A61K 9/1273
. . . .
{
Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances( polymers grafted or coated on phosphatidyl liposomes A61K 9/1271 , on non-phosphatidyl liposomes A61K 9/1272 )
}
A61K 9/1274
. . .
{
Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
}
A61K 9/1275
. . .
{
Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
}
A61K 9/1276
. . .
{
Globules of milk or constituents thereof
}
Collapse
A61K 9/1277
. . .
{
Processes for preparing; Proliposomes
}
A61K 9/1278
. . . .
{
Post-loading, e.g. by ion or pH gradient
}
Collapse
A61K 9/14
.
Particulate form, e.g. powders,
{
Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles( microspheres A61K 9/16 ; microcapsules A61K 9/50 ; nanocapsules, nanoparticles of the matrix type A61K 9/51 )
}
Collapse
A61K 9/141
. .
{
Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers( ( co ) spray-dried products A61K 9/16 , ( co ) lyophilised products A61K 9/19 ; the carrier being chemically bound to the active ingredient A61K 47/48 )
}
A61K 9/143
. . .
{
with inorganic compounds
}
A61K 9/145
. . .
{
with organic compounds
}
A61K 9/146
. . .
{
with organic macromolecular compounds
}
A61K 9/148
. . .
{
with compounds of unknown constitution, e.g. material from plants or animals( with oils, fats, waxes, shellac A61K 9/145 )
}
Collapse
A61K 9/16
. .
Agglomerates ; Granulates ; Microbeadlets;
{
Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,( multiple )emulsion solvent evaporation or extraction( A61K 9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K 9/50 ; mixture of different granules, microcapsules, ( coated ) microparticles A61K 9/5084; nanoparticles A61K 9/51 )
}
Collapse
A61K 9/1605
. . .
{
Excipients; Inactive ingredients
}
A61K 9/1611
. . . .
{
Inorganic compounds
}
Collapse
A61K 9/1617
. . . .
{
Organic compounds, e.g. phospholipids, fats
}
A61K 9/1623
. . . . .
{
Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
}
Collapse
A61K 9/1629
. . . .
{
Organic macromolecular compounds
}
A61K 9/1635
. . . . .
{
obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
}
Collapse
A61K 9/1641
. . . . .
{
obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
}
A61K 9/1647
. . . . . .
{
Polyesters, e.g. poly(lactide-co-glycolide)
}
A61K 9/1652
. . . . .
{
Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin( homeopathic globules A61K 9/1623 )
}
A61K 9/1658
. . . . .
{
Proteins, e.g. albumin, gelatin
}
A61K 9/1664
. . . .
{
Compounds of unknown constitution, e.g. material from plants or animals( oils, fats, waxes, shellac A61K 9/1617 )
}
Collapse
A61K 9/167
. . .
{
with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface( with further drug-free outer coating A61K 9/5073 )
}
A61K 9/1676
. . . .
{
having a drug-free core with discrete complete coating layer containing drug( adsorbates of liquid drug formulations on inert powders without simultaneous granulation step A61K 9/141; with further drug-free outer coating A61K 9/5078 ; drug conjugated to non-active particles A61K 47/48853 )
}
Collapse
A61K 9/1682
. . .
{
Processes
}
A61K 9/1688
. . . .
{
resulting in pure drug agglomerate optionally containing up to 5% of excipient
}
A61K 9/1694
. . . .
{
resulting in granules or microspheres of the matrix type containing more than 5% of excipient
}
A61K 9/19
. .
lyophilised,
{
i.e. freeze-dried, solutions or dispersions( lyophilised products with subsequent particle size reduction A61K 9/14 ; granules or pellets made by lyphilisation A61K 9/1682; solid oral dosage forms made by lyophilisation A61K 9/2095; lyophilisation additives A61K 47/00 )
}
Collapse
A61K 9/20
.
Pills, tablets,
{
discs, rods( A61K 9/0004 , A61K 9/0007 , A61K 9/0056 , A61K 9/0065 take precedence; for reconstitution of a drink A61K 9/0095 )
}
Collapse
A61K 9/2004
. .
{
Excipients; Inactive ingredients
}
A61K 9/2009
. . .
{
Inorganic compounds
}
Collapse
A61K 9/2013
. . .
{
Organic compounds, e.g. phospholipids, fats
}
A61K 9/2018
. . . .
{
Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
}
Collapse
A61K 9/2022
. . .
{
Organic macromolecular compounds
}
A61K 9/2027
. . . .
{
obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
}
Collapse
A61K 9/2031
. . . .
{
obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
}
A61K 9/2036
. . . . .
{
Silicones; Polysiloxanes
}
A61K 9/204
. . . . .
{
Polyesters, e.g. poly(lactide-co-glycolide)
}
A61K 9/2045
. . . . .
{
Polyamides; Polyaminoacids, e.g. polylysine
}
Collapse
A61K 9/205
. . . .
{
Polysaccharides, e.g. alginate, gums; Cyclodextrin
}
A61K 9/2054
. . . . .
{
Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
}
A61K 9/2059
. . . . .
{
Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
}
A61K 9/2063
. . . .
{
Proteins, e.g. gelatin
}
A61K 9/2068
. . .
{
Compounds of unknown constitution, e.g. material from plants or animals( oils, fats, waxes, shellac A61K 9/2013 )
}
Collapse
A61K 9/2072
. .
{
characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms( A61K 9/0004 , A61K 9/0056 , A61K 9/0065 take precedence )
}
Collapse
A61K 9/2077
. . .
{
Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
}
A61K 9/2081
. . . .
{
with microcapsules or coated microparticles according to A61K 9/50
}
Collapse
A61K 9/2086
. . .
{
Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat( active cores with a complete drug-free outer coat A61K 9/28 )
}
A61K 9/209
. . . .
{
containing drug in at least two layers or in the core and in at least one outer layer
}
A61K 9/2095
. .
{
Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing( mechanical aspects A61J 3/00 )
}
Collapse
A61K 9/28
. .
Dragees ; Coated pills or tablets
{
e.g. with film or compression coating( A61K 9/2072 takes precedence, e.g. partially coated tablets A61K 9/2072 , coated multilayer tablets A61K 9/2086 , tablets with drug-coated core A61K 9/209 )
}
Collapse
A61K 9/2806
. . .
{
Coating materials
}
A61K 9/2813
. . . .
{
Inorganic compounds
}
Collapse
A61K 9/282
. . . .
{
Organic compounds, e.g. fats
}
A61K 9/2826
. . . . .
{
Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
}
Collapse
A61K 9/2833
. . . .
{
Organic macromolecular compounds
}
Collapse
A61K 9/284
. . . . .
{
obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
}
A61K 9/2846
. . . . . .
{
Poly(meth)acrylates
}
A61K 9/2853
. . . . .
{
obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
}
Collapse
A61K 9/286
. . . . .
{
Polysaccharides, e.g. gums; Cyclodextrin
}
A61K 9/2866
. . . . . .
{
Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
}
A61K 9/2873
. . . . .
{
Proteins, e.g. gelatin
}
A61K 9/288
. . . .
{
Compounds of unknown constitution, e.g. material from plants or animals( oils, fats, waxes, shellac A61K 9/282 )
}
A61K 9/2886
. . .
{
having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer( of the type active core-drug layer-inactive layer A61K 9/209 )
}
A61K 9/2893
. . .
{
Tablet coating processes( mechanical aspects A61J 3/06 )
}
Collapse
A61K 9/48
.
Preparations in capsules, e.g. of gelatin, of chocolate;
{
( A61K 9/0004 takes precedence; bite capsules A61K 9/0056 )
}
A61K 9/4808
. .
{
characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release( capsules filled with granules or microparticles A61K 9/16 ; filled with microcapsules or coated microparticles A61K 9/50 ; with mixture of different granules, microcapsules, ( coated ) microparticles A61K 9/5084 )
}
Collapse
A61K 9/4816
. .
{
Wall or shell material
}
A61K 9/4825
. . .
{
Proteins, e.g. gelatin( gelatin capsule shells with substantial amounts of other macromolecular substances A61K 9/4816 )
}
A61K 9/4833
. .
{
Encapsulating processes; Filling of capsules( mechanical aspects A61J 3/07 )
}
Collapse
A61K 9/4841
. .
{
Filling excipients; Inactive ingredients
}
A61K 9/485
. . .
{
Inorganic compounds
}
A61K 9/4858
. . .
{
Organic compounds
}
A61K 9/4866
. . .
{
Organic macromolecular compounds
}
A61K 9/4875
. . .
{
Compounds of unknown constitution, e.g. material from plants or animals( oils, fats, waxes, shellac A61K 9/4858 )
}
A61K 9/4883
. .
{
Capsule finishing, e.g. dyeing, aromatising, polishing
}
A61K 9/4891
. .
{
Coated capsules; Multilayered drug free capsule shells( with drug coating for immediate release A61K 9/4808; osmotic devices A61K 9/0004 )
}
Collapse
A61K 9/50
. .
Microcapsules
{
having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals( A61K 9/2081 takes precedence; particles with a single coating comprising drug A61K 9/167 )
}
Collapse
A61K 9/5005
. . .
{
Wall or coating material
}
A61K 9/501
. . . .
{
Inorganic compounds
}
A61K 9/5015
. . . .
{
Organic compounds, e.g. fats, sugars
}
Collapse
A61K 9/5021
. . . .
{
Organic macromolecular compounds
}
A61K 9/5026
. . . . .
{
obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
}
A61K 9/5031
. . . . .
{
obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
}
Collapse
A61K 9/5036
. . . . .
{
Polysaccharides, e.g. gums, alginate; Cyclodextrin
}
Collapse
A61K 9/5042
. . . . . .
{
Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
}
A61K 9/5047
. . . . . . .
{
Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
}
Collapse
A61K 9/5052
. . . . .
{
Proteins, e.g. albumin
}
A61K 9/5057
. . . . . .
{
Gelatin
}
Collapse
A61K 9/5063
. . . .
{
Compounds of unknown constitution, e.g. material from plants or animals( oils, fats, waxes, shellac A61K 9/5015 )
}
A61K 9/5068
. . . . .
{
Cell membranes or bacterial membranes enclosing drugs( with additional exogenous lipids A61K 9/127 ; virus envelopes A61K 9/5184 )
}
Collapse
A61K 9/5073
. . .
{
having two or more different coatings optionally including drug-containing subcoatings
}
A61K 9/5078
. . . .
{
with drug-free core
}
A61K 9/5084
. . .
{
Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or( coated ) microparticles according to A61K 9/16 or A61K 9/50 , e.g. for obtaining a specific release pattern or for combining different drugs ( tablets containing such a mixture A61K 9/2077 )
}
A61K 9/5089
. . .
{
Processes
}
A61K 9/5094
. . .
{
Microcapsules containing magnetic carrier material, e.g. ferrite for drug targetting
}
Collapse
A61K 9/51
. . .
Nanocapsules;
{
Nanoparticles;( nanotubes A61K 9/0092 ; polymeric micelles A61K 9/1075 ; polymersomes A61K 9/1273 ; pure drug nanoparticles A61K 9/14 ; drug nanoparticles with adsorbed surface modifiers A61K 9/141 ; conjugates, e.g. between drug and non-active nanoparticles, A61K 47/48 ; preparations for in vivo diagnosis A61K 49/00 ; with radioactive substances A61K 51/00 )
}
Collapse
A61K 9/5107
. . . .
{
Excipients; Inactive ingredients
}
A61K 9/5115
. . . . .
{
Inorganic compounds
}
A61K 9/5123
. . . . .
{
Organic compounds, e.g. fats, sugars
}
Collapse
A61K 9/513
. . . . .
{
Organic macromolecular compounds; Dendrimers
}
A61K 9/5138
. . . . . .
{
obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
}
Collapse
A61K 9/5146
. . . . . .
{
obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
}
A61K 9/5153
. . . . . . .
{
Polyesters, e.g. poly(lactide-co-glycolide)
}
A61K 9/5161
. . . . . .
{
Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
}
A61K 9/5169
. . . . . .
{
Proteins, e.g. albumin, gelatin
}
Collapse
A61K 9/5176
. . . . .
{
Compounds of unknown constitution, e.g. material from plants or animals( oils, fats, waxes, shellac A61K 9/5123 )
}
A61K 9/5184
. . . . . .
{
Virus capsids or envelopes enclosing drugs( with additional exogenous lipids A61K 9/127 ; bacterial membranes A61K 9/5068 )
}
A61K 9/5192
. . . .
{
Processes
}
Collapse
A61K 9/70
.
Web, sheet or filament bases;
{
Films; Fibres of the matrix type containing drug;( hollow drug-filled fibres A61K 9/0092 ; bandages, dressings or absorbent pads A61F 13/00 , chemical aspects thereof A61L 15/00 )
}
A61K 9/7007
. .
{
Drug-containing films, membranes or sheets( A61K 9/0041 , A61K 9/0043 , A61K 9/006 , A61K 9/0063 take precedence )
}
A61K 9/7015
. .
{
Drug-containing film-forming compositions, e.g. spray-on
}
Collapse
A61K 9/7023
. .
{
Transdermal patches and similar drug-containing composite devices, e.g. cataplasms( galenical aspects of iontophoretic devices A61K 9/0009 ; microneedle arrays A61K 9/0021 ; buccal patches A61K 9/006 )
}
Collapse
A61K 9/703
. . .
{
characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
}
Collapse
A61K 9/7038
. . . .
{
Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
}
Collapse
A61K 9/7046
. . . . .
{
the adhesive comprising macromolecular compounds
}
Collapse
A61K 9/7053
. . . . . .
{
obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
}
A61K 9/7061
. . . . . . .
{
Polyacrylates
}
A61K 9/7069
. . . . . .
{
obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
}
A61K 9/7076
. . . . .
{
the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
}
A61K 9/7084
. . . .
{
Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
}
A61K 9/7092
. . . .
{
Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
}
Collapse
Medicinal preparations containing organic active ingredients
NOTE
-

When classifying in groups A61K 31/00 to A61K 41/00 the symbol A61K 2300/00 may be added, using Combination Sets, to indicate a mixture of active ingredients.

In the preparation of new organic compounds and their use in medicinal preparations, classification is only made in the relevant subclasses C07C to C07J according to the type of compound. However, the inventions dealing with medicinal preparations containing at least two active organic ingredients are always classified in this group in addition to the classification for the type of compounds in C07C to C07J .

Attention is drawn to the notes in class C07 , particularly to the definition of steroids given in Note (1) following the title of C07J and to the definition of carbohydrates and sugars given in the notes following the title of C07H .

Salts and complexes of organic active compounds are always classified according to the free active compounds. If a complex is formed between two or more active compounds, then they are classified according to all compounds forming the salts or complexes followed by the symbol A61K 2300/00 (i.e. as a mixture of active organic compounds). According to the last place rule, organic active compounds forming salts with heavy metals should be classified in A61K 33/24 to A61K 33/38 and not in subgroups A61K 31/28 to A61K 31/32 , A61K 31/555 or A61K 31/714 .
This does not apply to complexes, as apparent from the A61K 31/00 scheme, wherein the complexes hemin and hematin are classified in A61K 31/555 and cyanocobalamin in A61K 31/714 .

From January 2003 onwards, the EPO copies into CPC the IPC classification of the first document received (family representative). However, blends of active ingredients receive the additional symbol A61K 2300/00 as Combination Set.


Collapse
A61K 31/01
.
Hydrocarbons
A61K 31/015
. .
carbocyclic
Collapse
A61K 31/02
.
Halogenated hydrocarbons
Collapse
A61K 31/025
. .
carbocyclic
A61K 31/03
. . .
aromatic
A61K 31/035
. .
having aliphatic unsaturation
A61K 31/04
.
Nitro compounds
Collapse
A61K 31/045
.
Hydroxy compounds, e.g. alcohols ; Salts thereof, e.g. alcoholates
A61K 31/047
. .
having two or more hydroxy groups, e.g. sorbitol
Collapse
A61K 31/05
. .
Phenols
A61K 31/055
. . .
the aromatic ring being substituted by halogen
A61K 31/06
. . .
the aromatic ring being substituted by nitro groups
A61K 31/065
. .
Diphenyl-substituted acyclic alcohols
A61K 31/07
. .
Retinol compounds, e.g. vitamin A( retinoic acids A61K 31/203 )
Collapse
A61K 31/075
.
Ethers or acetals
A61K 31/08
. .
acyclic, e.g. paraformaldehyde
Collapse
A61K 31/085
. .
having an ether linkage to aromatic ring nuclear carbon
A61K 31/09
. . .
having two or more such linkages
Collapse
A61K 31/095
.
Sulfur, selenium, or tellurium compounds, e.g. thiols
A61K 31/10
. .
Sulfides ; Sulfoxides ; Sulfones
A61K 31/105
. .
Persulfides( thiuram disulfides A61K 31/145 ; thiosulfonic acids A61K 31/185 )
Collapse
A61K 31/11
.
Aldehydes
A61K 31/115
. .
Formaldehyde
Collapse
A61K 31/12
.
Ketones
A61K 31/121
. .
acyclic
Collapse
A61K 31/122
. .
having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/125
. . .
Camphor ; Nuclear substituted derivatives thereof
Collapse
A61K 31/13
.
Amines
{
( A61K 31/04 takes precedence )
}
A61K 31/131
. .
acylic
A61K 31/132
. .
having two or more amino groups, e.g. spermidine, putrescine
A61K 31/133
. .
having hydroxy groups, e.g. sphingosine
Collapse
A61K 31/135
. .
having aromatic rings
{
e.g. ketamine, nortriptyline( methadone A61K 31/137 )
}
A61K 31/136
. . .
having the amino group directly attached to the aromatic ring, e.g. benzeneamine
A61K 31/137
. . .
Arylalkylamines, e.g. amphetamine, epihephrine, salbutamol, ephedrine
{
or methadone
}
A61K 31/138
. . .
Aryloxyalkylamines, e.g. propanolol, tamoxifen, phenoxybenzamine( atenolol A61K 31/165 ; pindolol A61K 31/404 ; timolol A61K 31/5377 )
A61K 31/14
. .
Quaternary ammonium compounds, e.g. edrophonium, choline( betaines A61K 31/205 )
A61K 31/145
. .
having sulfur, e.g. thiurams( >N-C(S)-S-C(S)-N< and >N-C(S)-S-S-C(S)-N< ), Sulfinylamines (-N=SO), Sulfonylamines (-N=SO2)( isothiourea A61K 31/155 )
A61K 31/15
. .
Oximes (>C=N-O) ; Hydrazines (>N-N<) ; Hydrazones (>N-N=)
{
Imines (C-N=C)
}
A61K 31/155
. .
Amidines (-N=C-N-), e.g. guanidine( H2N-C(=NH)-NH2 ), isourea( N=C(OH)-NH2 ), isothiourea( -N=C(SH)-NH2 )
Collapse
A61K 31/16
.
Amides, e.g. hydroxamic acids
A61K 31/164
. .
of a carboxlic acid with an aminoalcohol, e.g. ceramides
Collapse
A61K 31/165
. .
having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/166
. . .
having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
A61K 31/167
. . .
having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
Collapse
A61K 31/17
. .
having the group >N-C( O )-N< or >N-C(S)-N<, e.g. urea, thiourea, carmustine( isoureas, isothioureas A61K 31/155 ; sulfonylureas A61K 31/64 )
A61K 31/175
. . .
having the group , >N-C(O)-N=N- or , e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones ; Thioanalogues thereof
A61K 31/18
. .
Sulfonamides( compounds containing a para-N-benzene-sulfonyl-N- group A61K 31/63 )
Collapse
A61K 31/185
.
Acids ; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids( hydroxamic acids A61K 31/16 ; peroxy acids A61K 31/327 )
NOTE
-
Cyclic anhydrides are considered to be heterocyclic rings

Collapse
A61K 31/19
. .
Carboxylic acids, e.g. valproic acid( Salicylic acid A61K 31/60 )
A61K 31/191
. . .
having two or more hydroxy groups, e.g. gluconic acid
A61K 31/192
. . .
having aromatic groups, e.g. sulindac, 2-arylpropionic acids, ethacrynic acid
A61K 31/194
. . .
having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
Collapse
A61K 31/195
. . .
having an amino group
A61K 31/196
. . . .
the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
Collapse
A61K 31/197
. . . .
the amino and the carboxyl group being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid( GABA ), beta-alanine, epsilon-aminocaproic acid, pantothenic acid( carnitine A61K 31/205 )
A61K 31/198
. . . . .
Alpha-aminoacids, e.g. alanine, edetic acids( EDTA ),( betaine A61K 31/205 ; proline A61K 31/401 ; tryptophan A61K 31/405 ; histidine A61K 31/4172 ; peptides not degraded to individual aminoacids A61K 38/00 )
Collapse
A61K 31/20
. . .
having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
A61K 31/201
. . . .
having one or two double bonds, e.g. oleic, linoleic acids
A61K 31/202
. . . .
having three or more double bonds, e.g. linolenic( eicosanoids, e.g. leukotrienes A61K 31/557 )
A61K 31/203
. . . .
Retinoic acids
{
Salts thereof
}
A61K 31/205
. .
Amine addition salts of organic acids ; Inner quaternary ammonium salts, e.g. betaine, carnitine
Collapse
A61K 31/21
.
Esters, e.g. nitroglycerine, selenocyanates
Collapse
A61K 31/215
. .
of carboxylic acids
A61K 31/216
. . .
of acids having aromatic rings, e.g. benactizyne, clofibrate
Collapse
A61K 31/22
. . .
of acyclic acids, e.g. pravastatin
A61K 31/221
. . . .
with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
A61K 31/222
. . . .
with compounds having aromatic groups, e.g. dipivefrine, ibopamine
A61K 31/223
. . . .
of alpha-aminoacids
A61K 31/225
. . . .
Polycarboxylic acids
Collapse
A61K 31/23
. . . .
of acids having a carboxyl group bound to a chain of seven or more carbon atoms
A61K 31/231
. . . . .
having one or two double bonds
A61K 31/232
. . . . .
having three or more double bonds, e.g. etretinate
Collapse
A61K 31/235
. . .
having an aromatic ring attached to a carboxyl group
Collapse
A61K 31/24
. . . .
having an amino or nitro group
A61K 31/245
. . . . .
Amino benzoic acid types, e.g. procaine, novocaine( salicylic acid esters A61K 31/60 )
A61K 31/25
. . .
with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
A61K 31/255
. .
of sulfoxy acids or sulfur analogues thereof
A61K 31/26
. .
Cyanate or isoyanate esters ; Thiocyanate or isothiocyanate esters
A61K 31/265
. .
of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
A61K 31/27
. .
of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
Collapse
A61K 31/275
.
Nitriles ; Isonitriles
A61K 31/277
. .
having a ring, e.g. verapamil
Collapse
A61K 31/28
.
Compounds containing heavy metals
A61K 31/282
. .
Platinum compounds
A61K 31/285
. .
Arsenic compounds
A61K 31/29
. .
Antimony or bismuth compounds
A61K 31/295
. .
Iron group metal compounds
A61K 31/30
. .
Copper compounds
Collapse
A61K 31/305
. .
Mercury compounds
A61K 31/31
. . .
containing nitrogen
A61K 31/315
. .
Zinc compounds
A61K 31/32
. .
Tin compounds
A61K 31/325
.
Carbamic acids ; Thiocarbamic acids ; Anhydrides or salts thereof( thiurams A61K 31/145 )
A61K 31/327
.
Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
Collapse
A61K 31/33
.
Heterocyclic compounds
Collapse
A61K 31/335
. .
having oxygen as the only ring hetero atom, e.g. fungichromin
A61K 31/336
. . .
having three-membered rings, e.g. oxirane, fumagillin
A61K 31/337
. . .
having four-membered rings, e.g. taxol
Collapse
A61K 31/34
. . .
having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
A61K 31/341
. . . .
not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A61K 31/343
. . . .
condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/345
. . . .
Nitrofurans( nitrofurantoin A61K 31/4178 )
Collapse
A61K 31/35
. . .
having six-membered rings with one oxygen as the only ring hetero atom
A61K 31/351
. . . .
not condensed with another ring
Collapse
A61K 31/352
. . . .
condensed with carbocyclic rings, e.g. cannabinols, methantheline
Collapse
A61K 31/353
. . . . .
3,4-Dihydrobenzopyrans, e.g. chroman, catechin
A61K 31/355
. . . . . .
Tocopherols, e.g. vitamin E
Collapse
A61K 31/357
. . .
having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/36
. . . .
Compounds containing methylenedioxyphenyl groups, e.g. sesamin
Collapse
A61K 31/365
. . .
Lactones
Collapse
A61K 31/366
. . . .
having six-membered rings, e.g. delta-lactones
A61K 31/37
. . . . .
Coumarins, e.g. psoralen
A61K 31/375
. . . .
Ascorbic acid, i.e. vitamin C ; Salts thereof
Collapse
A61K 31/38
. .
having sulfur as a ring hetero atom
A61K 31/381
. . .
having five-membered rings
A61K 31/382
. . .
having six-membered rings, e.g. thioxanthenes( thiotixene A61K 31/496 )
A61K 31/385
. . .
having two or more sulfur atoms in the same ring
A61K 31/39
. . .
having oxygen in the same ring
Collapse
A61K 31/395
. .
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins( rifampin A61K 31/496 )
A61K 31/396
. . .
having thre-membered rings, e.g. aziridine
A61K 31/397
. . .
having four-membered rings, e.g. azetidine
Collapse
A61K 31/40
. . .
having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/401
. . . .
Proline ; Derivatives thereof, e.g. captopril
A61K 31/4015
. . . .
having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
A61K 31/402
. . . .
1-aryl substituted, e.g. piretanide
A61K 31/4025
. . . .
not condensed and containing further heterocyclic rings, e.g. cromakalim
Collapse
A61K 31/403
. . . .
condensed with carbocyclic rings, e.g. carbazole
A61K 31/4035
. . . . .
Isoindoles, e.g. phthalimide
Collapse
A61K 31/404
. . . . .
Indoles, e.g. pindolol
A61K 31/4045
. . . . . .
Indole-alkylamines ; Amides thereof, e.g. serotonin, melatonin
A61K 31/405
. . . . . .
Indole-alkanecarboxylic acids ; Derivatives thereof, e.g. tryptophan, indomethacin
A61K 31/407
. . . .
condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 31/409
. . . .
having four such rings, e.g. phorphine derivatives, bilirubin, biliverdine( hemin, hematin A61K 31/555 )
Collapse
A61K 31/41
. . .
having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
Collapse
A61K 31/415
. . . .
1,2-Diazoles
A61K 31/4152
. . . . .
having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
A61K 31/4155
. . . . .
non condensed and containing further heterocyclic rings
A61K 31/416
. . . . .
condensed with carbocyclic ring systems, e.g. indazole
A61K 31/4162
. . . . .
condensed with heterocyclic ring systems
Collapse
A61K 31/4164
. . . .
1,3-Diazoles
A61K 31/4166
. . . . .
having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
A61K 31/4168
. . . . .
having a nitrogen attached in position 2, e.g. clonidine
A61K 31/417
. . . . .
Imidazole-alkylamines, e.g. histamine, phentolamine
A61K 31/4172
. . . . .
Imidazole-alkanecarboxylic acids, e.g. histidine
A61K 31/4174
. . . . .
Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
A61K 31/4178
. . . . .
not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/4184
. . . . .
condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/4188
. . . . .
condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
A61K 31/4192
. . . .
1,2,3-Triazoles
A61K 31/4196
. . . .
1,2,4-Triazoles
Collapse
A61K 31/42
. . . .
Oxazoles
A61K 31/421
. . . . .
1,3-Oxazoles, e.g. pemoline, trimethadione
A61K 31/422
. . . . .
not condensed and containing further heterocyclic rings
A61K 31/423
. . . . .
condensed with carbocyclic rings
A61K 31/424
. . . . .
condensed with heterocyclic ring systems, e.g. clavulanic acid
A61K 31/4245
. . . .
Oxadiazoles
Collapse
A61K 31/425
. . . .
Thiazoles
A61K 31/426
. . . . .
1,3-Thiazoles
A61K 31/427
. . . . .
not condensed and containing further heterocyclic rings
A61K 31/428
. . . . .
condensed with carbocyclic rings
Collapse
A61K 31/429
. . . . .
condensed with heterocyclic ring systems
Collapse
A61K 31/43
. . . . . .
Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula e.g. penicillins, penems
A61K 31/431
. . . . . . .
containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
A61K 31/433
. . . .
Thidiazoles
Collapse
A61K 31/435
. . .
having six-membered rings with one nitrogen as the only ring hetero atom
Collapse
A61K 31/4353
. . . .
ortho- or peri-condensed with heterocyclic ring systems
A61K 31/4355
. . . . .
the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
A61K 31/436
. . . . .
the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e..g. rapamycin
A61K 31/4365
. . . . .
the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
A61K 31/437
. . . . .
the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4375
. . . . .
the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/438
. . . .
the ring being spiro-condensed with carbocyclic ring systems
A61K 31/439
. . . .
the ring forming part of a bridged ring system, e.g. quinuclidine( 8-azabicyclo [3.2.1] octanes A61K 31/46 )
Collapse
A61K 31/44
. . . .
Non condensed pyridines ; Hydrogenated derivatives thereof
A61K 31/4402
. . . . .
only substituted in position 2, e.g. pheniramine, bisacodyl
A61K 31/4406
. . . . .
only substituted in position 3, e.g. zimeldine( nicotinic acid A61K 31/455 )
A61K 31/4409
. . . . .
only substituted in position 4, e.g. isoniazid, iproniazid
A61K 31/4412
. . . . .
having oxo groups directly attached to the heterocyclic ring
A61K 31/4415
. . . . .
Pyridoxine, i.e. Vitamin B6( pyridoxal phosphate A61K 31/675 )
A61K 31/4418
. . . . .
having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
A61K 31/4422
. . . . .
1,4-Dihydropyridines, e.g. nifedipine, nicardipine
A61K 31/4425
. . . . .
Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
Collapse
A61K 31/4427
. . . . .
containing further heterocyclic ring systems
A61K 31/443
. . . . . .
containing a five-membered ring with oxygen as a ring hetero atom
A61K 31/4433
. . . . . .
containing a six-membered ring with oxygen as a ring hetero atom
A61K 31/4436
. . . . . .
containing a heterocyclic ring having sulfur as a ring hetero atom
A61K 31/4439
. . . . . .
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole( nicotine A61K 31/465 )
A61K 31/444
. . . . . .
containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
Collapse
A61K 31/445
. . . . .
Non condensed piperidines, e.g. piperocaine
A61K 31/4453
. . . . . .
only substituted in position 1, e.g. propipocaine, diperodon
A61K 31/4458
. . . . . .
only substituted in position 2, e.g. methylphenidate
A61K 31/4462
. . . . . .
only substituted in position 3
A61K 31/4465
. . . . . .
only substituted in position 4
A61K 31/4468
. . . . . .
having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
A61K 31/45
. . . . . .
having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
A61K 31/451
. . . . . .
having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
A61K 31/4515
. . . . . .
having a butyrophenone group in position 1, e.g. haloperidol( pipamperone A61K 31/4545 )
A61K 31/452
. . . . . .
Piperidinium derivatives( pancuronium A61K 31/58 )
Collapse
A61K 31/4523
. . . . . .
containing further heterocyclic ring systems
A61K 31/4525
. . . . . . .
containing a five-membered ring with oxygen as a ring hetero atom
A61K 31/453
. . . . . . .
containing a six-membered ring with oxygen as a ring hetero atom
A61K 31/4535
. . . . . . .
containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
A61K 31/454
. . . . . . .
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4545
. . . . . . .
containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/455
. . . . .
Nicotinic acids, e.g. niacin ; Derivatives thereof, e.g. esters, amides
A61K 31/46
. . . .
8-Azabicyclo [3.2.1] octane ; Derivatives thereof, e.g. atropine, cocaine
A61K 31/465
. . . .
Nicotine ; Derivatives thereof
Collapse
A61K 31/47
. . . .
Quinolines ; Isoquinolines
A61K 31/4704
. . . . .
2-Quinolinones, e.g. carbostyril
A61K 31/4706
. . . . .
4-Aminoquinolines ; 8-Aminoquinolines, e.g. chloroquine, primaquine
A61K 31/4709
. . . . .
Non-condensed quinolines and containing further heterocyclic rings
Collapse
A61K 31/472
. . . . .
Non-condensed isoquinolines, e.g. papaverine
A61K 31/4725
. . . . . .
containing further heterocyclic rings
A61K 31/473
. . . . .
ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
Collapse
A61K 31/4738
. . . . .
ortho- or peri-condensed with heterocyclic ring systems
A61K 31/4741
. . . . . .
condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
A61K 31/4743
. . . . . .
condensed with ring systems having sulfur as a ring hetero atom
A61K 31/4745
. . . . . .
condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines( yohimbine derivatives, vinblastine A61K 31/475 ; ergoline derivatives A61K 31/48 )
A61K 31/4747
. . . . .
Spiro-condensed
A61K 31/4748
. . . . .
forming part of bridged ring systems( strychnine A61K 31/475 ; morphinan derivatives A61K 31/485 )
A61K 31/475
. . . . .
having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine( vincamine A61K 31/4375 )
A61K 31/48
. . . . .
Ergoline derivatives, e.g. lysergic acid, ergotamine
A61K 31/485
. . . . .
Morphinan derivatives, e.g. morphine, codeine
A61K 31/49
. . . . .
Cinchonan derivatives, e.g. quinine
Collapse
A61K 31/495
. . .
having six-membered rings with two
{
or more
}
nitrogen atoms as the only ring heteroatoms, e.g. piperazine
{
or tetrazines
}
( A61K 31/48 takes precedence )
{
( with three nitrogen atoms A61K 31/53 )
}
A61K 31/496
. . . .
Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
Collapse
A61K 31/4965
. . . .
Non-condensed pyrazines
A61K 31/497
. . . . .
containing further heterocyclic rings
A61K 31/498
. . . .
Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
A61K 31/4985
. . . .
Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/499
. . . .
Spiro-condensed pyrazines or piperazines
A61K 31/4995
. . . .
Pyrazines or piperazines forming part of bridged ring systems
Collapse
A61K 31/50
. . . .
Pyridazines ; Hydrogenated pyridazines
A61K 31/501
. . . . .
not condensed and containing further heterocyclic rings
A61K 31/502
. . . . .
ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 31/5025
. . . . .
ortho- or peri-condensed with heterocyclic ring systems
A61K 31/503
. . . . .
spiro-condensed
A61K 31/504
. . . . .
forming part of bridged ring systems
Collapse
A61K 31/505
. . . .
Pyrimidines ; Hydrogenated pyrimidines, e.g. trimethoprim
Collapse
A61K 31/506
. . . . .
not condensed and containing further heterocyclic rings
A61K 31/51
. . . . . .
Thiamines, e.g. vitamin B1
Collapse
A61K 31/513
. . . . .
having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/515
. . . . . .
Barbituric acids ; Derivatives thereof, e.g. sodium pentobarbital
A61K 31/517
. . . . .
ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
Collapse
A61K 31/519
. . . . .
ortho- or peri-condensed with heterocyclic rings
Collapse
A61K 31/52
. . . . . .
Purines, e.g. adenine
A61K 31/522
. . . . . . .
having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
A61K 31/525
. . . . . .
Isoalloxazines, e.g. riboflavins, vitamin B2
A61K 31/527
. . . . .
spiro-condensed
A61K 31/529
. . . . .
forming part of bridged ring systems
A61K 31/53
. . .
having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine,( melarsoprol A61K 31/555 )
{
( with four nitrogen atoms A61K 31/495 )
}
Collapse
A61K 31/535
. . .
having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
A61K 31/5355
. . . .
non-condensed oxazines and containing further heterocyclic rings
A61K 31/536
. . . .
ortho- or peri-condensed with carbocyclic ring systems
A61K 31/5365
. . . .
ortho- or peri-condensed with heterocyclic ring systems
A61K 31/537
. . . .
spiro-condensed or forming part of bridged ring systems
Collapse
A61K 31/5375
. . . .
1,4-Oxazines, e.g. morpholine
A61K 31/5377
. . . . .
not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/538
. . . . .
ortho- or peri-condensed with carbocyclic ring systems
A61K 31/5383
. . . . .
ortho- or peri-condensed with heterocyclic ring systems
A61K 31/5386
. . . . .
Spiro-condensed or forming part of bridged ring systems
A61K 31/539
. . . .
having two or more oxygen atoms in the same ring, e.g. dioxazines
A61K 31/5395
. . . .
having two or more nitrogen atoms in the same ring, e.g. oxadiazines
Collapse
A61K 31/54
. . .
having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
A61K 31/541
. . . .
non-condensed thiazines containing further heterocyclic rings
A61K 31/5415
. . . .
ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
Collapse
A61K 31/542
. . . .
ortho- or peri-condensed with heterocyclic ring systems
Collapse
A61K 31/545
. . . . .
Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. cephalosporins,
{
cefaclor, or cephalexine
}
A61K 31/546
. . . . . .
containing further heterocyclic rings, e.g. cephalothin
A61K 31/547
. . . .
spiro-condensed or forming part of bridged ring systems
A61K 31/548
. . . .
having two or more sulfur atoms in the same ring
A61K 31/549
. . . .
having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
Collapse
A61K 31/55
. . .
having seven-membered rings, e.g. azelastine, pentylenetetrazole
Collapse
A61K 31/551
. . . .
having two nitrogen atoms, e.g. dilazep
Collapse
A61K 31/5513
. . . . .
1,4-Benzodiazepines, e.g. diazepam
{
or clozapine
}
A61K 31/5517
. . . . . .
condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
A61K 31/553
. . . .
having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K 31/554
. . . .
having at least one nitrogen and one sulfur as ring hetero atoms, e.g. chlothiapine, diltiazem
A61K 31/555
. .
containing heavy metals, e.g. hemin, hematin, melarsoprol
Collapse
A61K 31/557
.
Eicosanoids, e.g. leukotrienes
{
or prostaglandins
}
A61K 31/5575
. .
having a cyclopentane, e.g. Prostaglandin E2, Prostaglandin F2-alpha
A61K 31/5578
. .
having a pentalene ring system, e.g. carbacyclin, iloprost
Collapse
A61K 31/558
. .
having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
A61K 31/5585
. . .
having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
A61K 31/559
. .
having heterocyclic rings containing hetero atoms other than oxygen
Collapse
A61K 31/56
.
Compounds containing cyclopenta[a]hydrophenanthrene ring systems ; Derivatives, e.g. steroids
NOTE
-
Attention is drawn to Note (1) following the title of subclass C07J which explains what is covered by the term "steroids"

Collapse
A61K 31/565
. .
not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
A61K 31/566
. . .
having an oxo group in position 17, e.g. estrone
A61K 31/567
. . .
substituted in position 17 alpha, e.g. mestranol, norethandrolone
Collapse
A61K 31/568
. . .
substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
A61K 31/5685
. . . .
having an oxo group in position 17, e.g. androsterone
A61K 31/569
. . . .
substituted in position 17 alpha, e.g. ethisterone
Collapse
A61K 31/57
. .
substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
A61K 31/573
. . .
substituted in position 21, e.g. cortisone, dexamethasone, prednisone
{
or aldosterone
}
A61K 31/575
. .
substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
Collapse
A61K 31/58
. .
containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
{
( digitoxin A61K 31/7048 )
}
A61K 31/585
. . .
containing lactone rings, e.g. oxandrolone, bufalin
Collapse
A61K 31/59
.
Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
A61K 31/592
. .
9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
A61K 31/593
. .
9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
Collapse
A61K 31/60
.
Salicylic acid ; Derivatives thereof
A61K 31/603
. .
having further aromatic rings, e.g. diflunisal
A61K 31/606
. .
having amino groups
A61K 31/609
. .
Amides, e.g. salicylamide
{
( labetalol, metoclopramide A61K 31/166 )
}
Collapse
A61K 31/612
. .
having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid( fosfosal A61K 31/661 )
A61K 31/616
. . .
by carboxylic acids, e.g. acetylsalicyclic acid
Collapse
A61K 31/618
. .
having the carboxyl group in position 1 esterified, e.g. salsalate
A61K 31/621
. . .
having the hydroxy group in position 2 esterified, e.g. benorylate
A61K 31/625
. .
having heterocyclic substituents, e.g. 4-salicycloylmorpholine,( sulfasalazine A61K 31/635 )
Collapse
A61K 31/63
.
Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
A61K 31/635
. .
having a heterocyclic ring, e.g. sulfasalazine
A61K 31/64
.
Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
A61K 31/65
.
Tetracyclines
A61K 31/655
.
Azo( -N=N- )
{
( sulfasalazine A61K 31/635 )
}
, diazo( =N2 ), azoxy( >N-O-N< or N(=O)-N< ), azido (-N3) or diazoamino (-N=N-N<) compounds
Collapse
A61K 31/66
.
Phosphorus compounds
Collapse
A61K 31/661
. .
Phosphorus acids or esters thereof not having P-C bonds, e.g. fosfosal, dichlorvos, malathion
{
or mevinphos
}
A61K 31/6615
. . .
Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
Collapse
A61K 31/662
. .
Phosphorus acids or esters thereof having P-C bonds, e.g. foscarnet, trichlorfon
A61K 31/663
. . .
Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
A61K 31/664
. .
Amides of phosphorus acids
A61K 31/665
. .
having oxygen as a ring hetero atom, e.g. fosfomycin
A61K 31/67
. .
having sulfur as a ring hetero atom
A61K 31/675
. .
having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
Collapse
A61K 31/683
. .
Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
A61K 31/685
. . .
one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 31/688
. . .
both hydroxy compounds having nitrogen atoms, e.g. sphingomyelin
A61K 31/69
.
Boron compounds
A61K 31/695
.
Silicon compounds
Collapse
A61K 31/70
.
Carbohydrates ; Sugars ; Derivatives thereof( sorbitol A61K 31/047 )
NOTE
-
In this group, the expressions are used with the meanings indicated in Note (3) following the title of the subclass C07H

A61K 31/7004
. .
Monosaccharide having only carbon, hydrogen and oxygen atoms
A61K 31/7008
. .
Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
A61K 31/7012
. .
Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid( gluconic acid A61K 31/191 ; ascorbic acid A61K 31/375 )
A61K 31/7016
. .
Disaccharides, e.g. lactose, lactulose( lactobionic acid A61K 31/7032 )
A61K 31/702
. .
Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
A61K 31/7024
. .
Esters of saccharides
Collapse
A61K 31/7028
. .
Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
A61K 31/7032
. . .
attached to a polyol, i.e. compound having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
Collapse
A61K 31/7034
. . .
attached to a carbocyclic compound, e.g. phloridzin
A61K 31/7036
. . . .
having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
A61K 31/704
. . . .
attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
{
( digitoxin A61K 31/7048 )
}
Collapse
A61K 31/7042
. .
Compounds having saccharide radicals and heterocyclic rings
A61K 31/7048
. . .
having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
{
digitoxin or digoxin
}
Collapse
A61K 31/7052
. . .
having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
A61K 31/7056
. . . .
containing five-membered rings with nitrogen as a ring hetero atom
Collapse
A61K 31/706
. . . .
containing six-membered rings with nitrogen as a ring hetero atom
Collapse
A61K 31/7064
. . . . .
containing condensed or non-condensed pyrimidines
Collapse
A61K 31/7068
. . . . . .
having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 31/7072
. . . . . . .
having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
Collapse
A61K 31/7076
. . . . . .
containing purines, e.g. adenosine, adenylic acid
A61K 31/708
. . . . . . .
having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
A61K 31/7084
. .
Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
Collapse
A61K 31/7088
. .
Compounds having three or more nucleosides or nucleotides
A61K 31/7105
. . .
Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/711
. . .
Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
A61K 31/7115
. . .
Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
A61K 31/712
. . .
Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
A61K 31/7125
. . .
Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
A61K 31/713
. . .
Double-stranded nucleic acids or oligonucleotides
Collapse
A61K 31/7135
. .
Compounds containing heavy metals
A61K 31/714
. . .
Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
Collapse
A61K 31/715
. .
Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages ; Derivatives thereof, e.g. ethers, esters
Collapse
A61K 31/716
. . .
Glucans
A61K 31/717
. . . .
Celluloses
A61K 31/718
. . . .
Starch or degraded starch, e.g. amylose, amylopectin
A61K 31/719
. . . .
Pullulans
A61K 31/721
. . . .
Dextrans
A61K 31/722
. . . .
Chitin, chitosan
A61K 31/723
. . . .
Xanthans
A61K 31/724
. . . .
Cyclodextrins
Collapse
A61K 31/726
. . .
Glycosaminoglycans, i.e. mucopolysaccharides( chondroitin sulfate, dermatan sulfate A61K 31/737 )
A61K 31/727
. . . .
Heparin ; Heparan
A61K 31/728
. . . .
Hyaluronic acid
A61K 31/729
. . .
Agar ; Agarose ; Agaropectin
A61K 31/731
. . .
Carrageenans
A61K 31/732
. . .
Pectin
A61K 31/733
. . .
Fructosans, e.g. inulin
A61K 31/734
. . .
Alginic acid
A61K 31/736
. . .
Glucomannans or galactomannans, e.g. locust bean gum, guar gum
A61K 31/737
. . .
Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate( A61K 31/727 takes precedence )
A61K 31/738
. . .
Cross-linked polysaccharides
A61K 31/739
. . .
Lipopolysaccharides
Collapse
A61K 31/74
.
Synthetic polymeric materials
Collapse
A61K 31/745
. .
Polymers of hydrocarbons
A61K 31/75
. . .
of ethene
Collapse
A61K 31/755
. .
Polymers containing halogen
A61K 31/76
. . .
of vinyl chloride
Collapse
A61K 31/765
. .
Polymers containing oxygen
A61K 31/77
. . .
of oxiranes
A61K 31/775
. . .
Phenolic resins
A61K 31/78
. . .
of acrylic acid or derivatives thereof
Collapse
A61K 31/785
. .
Polymers containing nitrogen
Collapse
A61K 31/787
. . .
containing heterocyclic rings having nitrogen as a ring hetero atom
A61K 31/79
. . . .
Polymers of vinyl pyrrolidone
A61K 31/795
. .
Polymers containing sulfur
A61K 31/80
. .
Polymers containing hetero atoms not provided for in groups A61K 31/755 to A61K 31/795
Collapse
Medicinal preparations containing inorganic active ingredients
A61K 33/02
.
Ammonia ; Compounds thereof
A61K 33/04
.
Sulfur, selenium or tellurium ; Compounds thereof
Collapse
A61K 33/06
.
Aluminium, calcium or magnesium ; Compounds thereof,
{
e.g. clay
}
A61K 33/08
. .
Oxides ; Hydroxides
A61K 33/10
. .
Carbonates ; Bicarbonates
A61K 33/12
. .
Magnesium silicate
A61K 33/14
.
Alkali metal chlorides ; Alkaline earth metal chlorides
A61K 33/16
.
Fluorine compounds
A61K 33/18
.
Iodine ; Compounds thereof
A61K 33/20
.
Elemental chlorine ; Inorganic compounds releasing chlorine
A61K 33/22
.
Boron compounds
Collapse
A61K 33/24
.
Heavy metals ; Compounds thereof
A61K 33/245
. .
{
Bismuth; Derivatives thereof
}
A61K 33/26
. .
Iron ; Compounds thereof
A61K 33/28
. .
Mercury ; Compounds thereof
A61K 33/30
. .
Zinc ; Compounds thereof
A61K 33/32
. .
Manganese ; Compounds thereof
A61K 33/34
. .
Copper ; Compounds thereof
A61K 33/36
. .
Arsenic ; Compounds thereof
A61K 33/38
. .
Silver ; Compounds thereof
A61K 33/40
.
Peroxides
A61K 33/42
.
Phosphorus ; Compounds thereof
A61K 33/44
.
Elemental carbon, e.g. charcoal, carbon black
Collapse
Medicinal preparations containing materials or reaction products thereof with undetermined constitution
NOTE
-
When classifying in this group, the last place rule (applied throughout A61K ) does not apply. Namely, classification is made for each active component or material.

WARNING
-

Groups A61K 35/13 , A61K 35/15 , A61K 35/17 , A61K 35/19 , A61K 35/33 , A61K 35/35 , A61K 35/51 , A61K 35/57 , A61K 35/61 do not correspond to former or future IPC. Concordance CPC : IPC for these groups is as follows: - A61K 35/13 : A61K 35/12 - A61K 35/15 : A61K 35/14 - A61K 35/17 : A61K 35/14 - A61K 35/19 : A61K 35/14 - A61K 35/33 : A61K 35/12 - A61K 35/35 : A61K 35/12 - A61K 35/51 : A61K 35/48 - A61K 35/57 : A61K 35/56 - A61K 35/61 : A61K 35/56

Collapse
A61K 35/02
.
from inanimate materials
Collapse
A61K 35/04
. .
Tars ; Bitumens ; Mineral oils ; Ammonium bituminisulfonates, e.g. ichthyol( carbon A61K 33/00 )
A61K 35/06
. . .
Mineral oils,
{
e.g. paraffinic oils, aromatic oils based on aromatic hydrocarbons( essential oils derived from plants A61K 36/00 )
}
A61K 35/08
. .
Mineral waters;
{
Sea water
}
A61K 35/10
. .
Peat ; Amber;
{
Turf; Humus( wood tar, sap or resin A61K 36/00 )
}
Collapse
A61K 2035/11
.
{
Medicinal preparations comprising living procariotic cells
}
A61K 2035/115
. .
{
Probiotics
}
Collapse
A61K 35/12
.
Materials from mammals;
{
compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells( uncharacterized stem cells A61K 35/545 ); Genetically modified cells( gene therapy C12N 5/10 ; vaccines or medicinal preparations containing antigens or antibodies A61K 39/00 )
}
{
Note: If the cells are characterized, classify under the corresponding tissue or tissue of origin
}
NOTE
-
When the cells are characterized, classification is given under the corresponding tissue or tissue of origin

A61K 2035/122
. .
{
for inducing tolerance or supression of immune responses
}
A61K 2035/124
. .
{
the cells being hematopoietic, bone marrow derived or blood cells
}
Collapse
A61K 2035/126
. .
{
Immunoprotecting barriers, e.g. jackets, diffusion chambers
}
A61K 2035/128
. . .
{
capsules, e.g. microcapsules
}
A61K 35/13
. .
{
Tumor cells, irrespective of tissue of origin( tumor vaccines A61K 39/00 )
}
Collapse
A61K 35/14
. .
Blood
{
( haemoglobin A61K 38/42 ; umbilical cord blood A61K 35/51 )
}
; Artificial blood( perfluorocarbons A61K 31/02 )]
A61K 35/15
. . .
{
Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen presenting cells, e.g. dendritic cells( presenting a specific antigen A61K 39/00 ; therapeutic combinations of antibodies, or fragments thereof, and blood-derived cells A61K 35/15 , A61K 39/00 or C07K 16/00 )
}
A61K 35/16
. . .
{
Blood plasma; Blood serum( umbilical cord blood A61K 35/51 )
}
A61K 35/17
. . .
{
Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon- and cytokine-activated lymphocytes( when activated by a specific antigen A61K 39/00 )
}
A61K 35/18
. . .
Erythrocytes
{
( hemoglobin A61K 38/42 )
}
A61K 35/19
. . .
{
Platelets; Megacaryocytes
}
A61K 35/20
. .
Milk ; Colostrum;
{
Whey
}
A61K 35/22
. .
{
Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
}
; Urine
A61K 35/24
. .
Mucus ; Mucous glands ; Bursa;
{
Synovial fluid
}
; Arthral fluid ; Excreta ; Spinal fluid
{
( saliva A61K 35/38 )
}
A61K 35/26
. .
Lymph;
{
Lymph nodes;
}
Thymus;
{
Spleen; Splenocytes; Thymocytes
}
A61K 35/28
. .
{
Bone
}
marrow;
{
Hematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
}
A61K 35/30
. .
Nerves ; Brain;
{
Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia, astrocytes; Choroid plexus; Spinal cord tissue
}
A61K 35/32
. .
Bones;
{
Osteocytes; Osteoblasts;
}
Tendons;
{
Tenocytes;
}
Teeth;
{
Odontoblasts;
}
Cartilage;
{
Chondrocytes; Synovial membrane
}
A61K 35/33
. .
{
Fibroblasts
}
A61K 35/34
. .
Muscles;
{
Smooth muscle cells
}
Heart;
{
Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes( vascular smooth muscle A61K 35/44 )
}
A61K 35/35
. .
{
Fat tissue; Adipocytes; Stromal cells; Connective tissues of general nature( adipose-derived stem cells A61K 35/28 , collagen A61K 38/39 )
}
A61K 35/36
. .
Skin ; Hair ; Nails ; Sebacious glands ; Cerumen;
{
Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ecdodermal cells( islets of Langerhans A61K 35/39 )
}
NOTE
-
Epithelial cells of specific tissues, e.g. lung epithelium, are classified under the respective tissue

Collapse
A61K 35/37
. .
Digestive system
A61K 35/38
. . .
Stomach ; Intestine;
{
Goblet cells; Oral mucosa; Saliva
}
A61K 35/39
. . .
Pancreas ; Islets of Langerhans
{
( Langerhans cells of epidermis A61K 35/36 )
}
A61K 35/407
. . .
Liver;
{
Hepatocytes
}
A61K 35/413
. . .
{
Gallbladder;
}
Bile
A61K 35/42
. .
{
Respiratory System:
}
e.g. Lungs;
{
Bronchi; Lung cells
}
A61K 35/44
. .
Vessels
{
e.g. blood vessels or lymphatic vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
}
Collapse
A61K 35/48
. .
Reproductive organs
A61K 35/50
. . .
Placenta ; Amniotic fluid;
{
Amnion, Amniotic stem cells; Placental stem cells
}
A61K 35/51
. . .
{
Umbilical cord; Umbilical cord blood; Umbilical stem cells
}
A61K 35/52
. . .
Sperm
{
Prostate, Seminal fluid; Leydig cells of testes
}
Collapse
A61K 35/54
. . .
Ovary ; Embryos;
{
Fetal cells; Germ cells
}
A61K 35/545
. . . .
{
Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterized stem cells
}
A61K 35/55
. .
Glands not provided for in any of the preceding subgroups of this main group
{
e.g. thyroid, parathyroid, pineal gland
}
Collapse
A61K 35/56
.
Materials from animals other than mammals
A61K 35/57
. .
{
Birds; Materials from birds, e.g. eggs or feathers
}
Collapse
A61K 35/58
. .
{
Reptiles
}
A61K 35/583
. . .
{
Snakes Lizards; Chameleons( therapeutic use of a snake venom protein A61K 38/00 )
}
A61K 35/586
. . .
{
Turtles, Tortoises
}
A61K 35/60
. .
Fish;
{
Seahorses; Fish eggs
}
Collapse
A61K 35/61
. .
{
Sea animals other than those covered by group A61K 35/60
}
A61K 35/612
. . .
{
Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
}
A61K 35/614
. . .
{
Cnidaria, e.g. sea anemones, corals, coral animals, jellyfish
}
A61K 35/616
. . .
{
Echinodermata, e.g. star fish, sea cucumbers, sea urchins
}
A61K 35/618
. . .
{
Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
}
A61K 35/62
. .
Leeches;
{
Worms, e.g. cestodes or tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
}
Collapse
A61K 35/64
. .
{
Arthropods
}
Collapse
A61K 35/642
. . .
{
Insects, e.g. bees, wasps or fleas
}
A61K 35/644
. . . .
{
Beeswax; Propolis; Royal jelly; Honey
}
A61K 35/646
. . .
{
arachnids, e.g. spiders, scorpions, ticks or mites
}
A61K 35/648
. . .
{
Myriapods, e.g. centipedes or millipedes
}
A61K 35/65
. .
{
Amphibians, e.g. toads, frogs, salamanders, newts
}
Collapse
A61K 35/66
.
Micro-organisms or materials thereof( mutated microorganisms or microorganisms per se C12R 1/00 ; microorganisms in food, for nutritional purposes A23L 1/3014 ; fungi, yeast or candida A61K 36/06 )]
NOTE
-
Classification is given in this group only the micro-organism is the active ingredient

A61K 35/68
. .
Protozoa
{
e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
}
Collapse
A61K 35/74
. .
Bacteria
{
( therapeutic use of a bacterial protein A61K 38/00 ; bacteria per se or mutant bacteria C12R 1/00 ; bacteria in food, for nutritional purposes A23L 1/3014 )
}
Collapse
A61K 35/741
. . .
{
Probiotics( as part of food or functional food A23L 1/3014 ; probiotic yeast, i.e. saccharomyces A61K 36/06 )
}
A61K 35/742
. . . .
{
Spore-forming bacteria, e.g. Bacillus coagulans or Lactobacillus sporogenes
}
Collapse
A61K 35/744
. . . .
{
Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci, leuconostoc
}
A61K 35/745
. . . . .
{
Bifidobacteria
}
A61K 35/747
. . . . .
{
Lactobacilli, e.g. L. acidophilus, L. brevis
}
A61K 35/748
. . .
{
Cyanobacteria; Spirulina; Blue-green algae; Blue-green bacteria( algae, microalgae or microphytes A61K 36/00 )
}
Collapse
A61K 35/76
. .
Viruses,
{
Bacteriophages;( viruses per se C12N 7/00 ; viral proteins per se C07K 14/005 ; use of virus as a vector C12N 15/86 ; use of virus or part thereof as vaccine A61K 39/12 ; therapeutic use of a viral protein A61K 38/16 )
}
A61K 35/761
. . .
{
Adenovirus
}
A61K 35/763
. . .
{
Herpes virus
}
A61K 35/765
. . .
{
Reovirus; Rotavirus
}
A61K 35/766
. . .
{
Rhabdovirus, e.g. vesicular stomatitis virus
}
A61K 35/768
. . .
{
Other oncolytic viruses
}
Collapse
Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
{
( antigens from pollen A61K 39/36 )
}
NOTE
-
In this group, common names of plants, where given, are presented in brackets following their corresponding Latin names.

Collapse
A61K 36/02
.
Algae
A61K 36/03
. .
Phaeophycota or phaeophyta( brown algae ), e.g. Fucus
A61K 36/04
. .
Rhodophycota or rhodophya( red algae ), e.g. Porphyra
A61K 36/05
. .
Chlorophycota or chlorophyta( green algae ), e.g. Chlorella
Collapse
A61K 36/06
.
Fungi, e.g. yeasts
Collapse
A61K 36/062
. .
Ascomycota
A61K 36/064
. . .
Saccharomycetales, e.g. baker's yeast
Collapse
A61K 36/066
. . .
Clavicipitaceae
A61K 36/068
. . . .
Cordyceps
Collapse
A61K 36/07
. .
Basidiomycota, e.g. Cryptococcus
A61K 36/074
. . .
Ganoderma
A61K 36/076
. . .
Poria
A61K 36/09
.
Lichens
A61K 36/10
.
Bryophyta
Collapse
A61K 36/11
.
Pteridophyta or Filicophyta (ferns)
Collapse
A61K 36/12
. .
Filicopsida or Pteridopsida
A61K 36/126
. . .
Drynaria
Collapse
A61K 36/13
.
Coniferophyta (gymnosperms)
A61K 36/14
. .
Cupressaceae( Cypress family ), e.g. juniper or cypress
A61K 36/15
. .
Pinaceae( Pine family ), e.g. pine or cedar
A61K 36/16
.
Ginkgophyta, e.g. Ginkgoaceae( Ginkgo family )
A61K 36/17
.
Gnetophyta, e.g. Ephedraceae( Mormon-tea tamily )
Collapse
A61K 36/18
.
Magnoliophyta (angiosperms)
Collapse
A61K 36/185
. .
Magnoliopsida (dicotyledons)
Collapse
A61K 36/19
. . .
Acanthaceae( Acanthus family )
A61K 36/195
. . . .
Strobilanthes
A61K 36/20
. . .
Aceraceae( Maple family )
A61K 36/21
. . .
Amaranthaceae( Amaranth family ), e.g. pigweed, rockwort or globe amaranth
A61K 36/22
. . .
Anacardiaceae( Sumac family ), e.g. smoketree, sumac or poison oak
Collapse
A61K 36/23
. . .
Apiaceae or Umbelliferae( Carrot family ), e.g. dill, chervil, coriander or cumin
A61K 36/232
. . . .
Angelica
A61K 36/233
. . . .
Bupleurum
A61K 36/234
. . . .
Cnidium (snowparsley)
A61K 36/235
. . . .
Foeniculum (fennel)
A61K 36/236
. . . .
Ligusticum (licorice-root)
A61K 36/237
. . . .
Notopterygium
A61K 36/238
. . . .
Saposhnikovia
A61K 36/24
. . .
Apocynaceae( Dogbane family ), e.g. plumeria or periwinkle
Collapse
A61K 36/25
. . .
Araliaceae( Ginseng family ), e.g. ivy, aralia, schefflera or tetrapanax
A61K 36/254
. . . .
Acanthopanax or Eleutherococcus
A61K 36/258
. . . .
Panax (ginseng)
Collapse
A61K 36/26
. . .
Aristolochiaceae( Birthwort family ), e.g. heartleaf
A61K 36/264
. . . .
Aristolochia( Dutchman's pipe )
A61K 36/268
. . . .
Asarum( wild ginger )
A61K 36/27
. . .
Asclepiadaceae( Milkweed family ), e.g. hoya
Collapse
A61K 36/28
. . .
Asteraceae or Compositae( Aster or Sunflower family ), e.g. chamomile, feverfew, yarrow or echinacea
A61K 36/282
. . . .
Artemisia, e.g. wormwood or sagebrush
A61K 36/284
. . . .
Atractylodes
A61K 36/285
. . . .
Aucklandia
A61K 36/286
. . . .
Carthamus( distaff thistle )
A61K 36/287
. . . .
Chrysanthemum, e.g. daisy
A61K 36/288
. . . .
Taraxacum (dandelion)
A61K 36/289
. . . .
Vladimiria
Collapse
A61K 36/29
. . .
Berberidaceae( Barberry family ), e.g. barberry, cohosh or mayapple
A61K 36/296
. . . .
Epimedium
A61K 36/30
. . .
Boraginaceae( Borage family ), e.g. comfrey, lungwort or forget-me-not
Collapse
A61K 36/31
. . .
Brassicaceae or Cruciferae( Mustard family ), e.g. broccoli, cabbage or kohlrabi
A61K 36/315
. . . .
Isatis, e.g. Dyer's woad
Collapse
A61K 36/32
. . .
Burseraceae( Frankincense family )
A61K 36/324
. . . .
Boswellia, e.g. frankincense
A61K 36/328
. . . .
Commiphora, e.g. mecca myrrh or balm of Gilead
A61K 36/33
. . .
Cactaceae( Cactus family ), e.g. pricklypear or Cereus
Collapse
A61K 36/34
. . .
Campanulaceae( Bellflower family )
A61K 36/342
. . . .
Adenophora
A61K 36/344
. . . .
Codonopsis
A61K 36/346
. . . .
Platycodon
Collapse
A61K 36/35
. . .
Caprifoliaceae( Honeysuckle family )
A61K 36/355
. . . .
Lonicera (honeysuckle)
A61K 36/36
. . .
Caryophyllaceae( Pink family ), e.g. babysbreath or soapwort
A61K 36/37
. . .
Celastraceae( Staff-tree or Bittersweet family ), e.g. tripterygium or spindletree
A61K 36/38
. . .
Clusiaceae, Hypericaceae or Guttiferae( Hypericum or Mangosteen family ), e.g. common St. Johnswort
A61K 36/39
. . .
Convolvulaceae( Morning-glory family ), e.g. bindweed
A61K 36/40
. . .
Cornaceae( Dogwood family )
A61K 36/41
. . .
Crassulaceae( Stonecrop family )
Collapse
A61K 36/42
. . .
Cucurbitaceae( Cucumber family )
A61K 36/424
. . . .
Gynostemma
A61K 36/428
. . . .
Trichosanthes
A61K 36/43
. . .
Cuscutaceae( Dodder family ), e.g. Cuscuta epithymum or greater dodder
A61K 36/44
. . .
Ebenaceae( Ebony family ), e.g. persimmon
A61K 36/45
. . .
Ericaceae or Vacciniaceae( Heath or Blueberry family ), e.g. blueberry, cranberry or bilberry
A61K 36/46
. . .
Eucommiaceae( Eucommia family ), e.g. hardy rubber tree
A61K 36/47
. . .
Euphorbiaceae( Spurge family ), e.g. Ricinus (castorbean)
Collapse
A61K 36/48
. . .
Fabaceae or Leguminosae( Pea or Legume family ) ; Caesalpiniaceae ; Mimosaceae ; Papilionaceae
A61K 36/481
. . . .
Astragalus (milkvetch)
A61K 36/482
. . . .
Cassia, e.g. golden shower tree
A61K 36/483
. . . .
Gleditsia (locust)
A61K 36/484
. . . .
Glycyrrhiza (licorice)
A61K 36/485
. . . .
Gueldenstaedtia
A61K 36/486
. . . .
Millettia
A61K 36/487
. . . .
Psoralea
A61K 36/488
. . . .
Pueraria (kudzu)
A61K 36/489
. . . .
Sophora, e.g. necklacepod or mamani
A61K 36/49
. . .
Fagaceae( Beech family ), e.g. oak or chestnut
Collapse
A61K 36/50
. . .
Fumariaceae( Fumitory family ), e.g. bleeding heart
A61K 36/505
. . . .
Corydalis
Collapse
A61K 36/51
. . .
Gentianaceae( Gentian family )
A61K 36/515
. . . .
Gentiana
A61K 36/52
. . .
Juglandaceae( Walnut family )
Collapse
A61K 36/53
. . .
Lamiaceae or Labiatae( Mint family ), e.g. thyme, rosemary or lavender
A61K 36/532
. . . .
Agastache, e.g. giant hyssop
A61K 36/533
. . . .
Leonurus (motherwort)
A61K 36/534
. . . .
Mentha (mint)
A61K 36/535
. . . .
Perilla( beefsteak plant )
A61K 36/536
. . . .
Prunella or Brunella (selfheal)
A61K 36/537
. . . .
Salvia (sage)
A61K 36/538
. . . .
Schizonepeta
A61K 36/539
. . . .
Scutellaria (skullcap)
A61K 36/54
. . .
Lauraceae( Laurel family ), e.g. cinnamon or sassafras
A61K 36/55
. . .
Linaceae( Flax family ), e.g. Linum
A61K 36/56
. . .
Loganiaceae( Logania family ), e.g. trumpetflower or pinkroot
Collapse
A61K 36/57
. . .
Magnoliaceae( Magnolia family )
A61K 36/575
. . . .
Magnolia
A61K 36/58
. . .
Meliaceae( Chinaberry or Mahogany family ), e.g. Azadirachta (neem)
A61K 36/59
. . .
Menispermaceae( Moonseed family ), e.g. hyperbaena or coralbead
Collapse
A61K 36/60
. . .
Moraceae( Mulberry family ), e.g. breadfruit or fig
A61K 36/605
. . . .
Morus (mulberry)
A61K 36/61
. . .
Myrtaceae( Myrtle family ), e.g. teatree or eucalyptus
A61K 36/62
. . .
Nymphaeaceae( Water-lily family )
Collapse
A61K 36/63
. . .
Oleaceae( Olive family ), e.g. jasmine, lilac or ash tree
A61K 36/634
. . . .
Forsythia
A61K 36/638
. . . .
Ligustrum, e.g. Chinese privet
A61K 36/64
. . .
Orobanchaceae( Broom-rape family )
A61K 36/65
. . .
Paeoniaceae( Peony family ), e.g. Chinese peony
A61K 36/66
. . .
Papaveraceae( Poppy family ), e.g. bloodroot
A61K 36/67
. . .
Piperaceae( Pepper family ), e.g. Jamaican pepper or kava
A61K 36/68
. . .
Plantaginaceae( Plantain Family )
A61K 36/69
. . .
Polygalaceae( Milkwort family )
Collapse
A61K 36/70
. . .
Polygonaceae( Buckwheat family ), e.g. spineflower or dock
A61K 36/704
. . . .
Polygonum, e.g. knotweed
A61K 36/708
. . . .
Rheum (rhubarb)
Collapse
A61K 36/71
. . .
Ranunculaceae( Buttercup family ), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
A61K 36/714
. . . .
Aconitum (monkshood)
A61K 36/716
. . . .
Clematis( leather flower )
A61K 36/718
. . . .
Coptis (goldthread)
Collapse
A61K 36/72
. . .
Rhamnaceae( Buckthorn family ), e.g. buckthorn, chewstick or umbrella-tree
A61K 36/725
. . . .
Ziziphus, e.g. jujube
Collapse
A61K 36/73
. . .
Rosaceae( Rose family ), e.g. strawberry, chokeberry, blackberry, pear or firethorn
A61K 36/732
. . . .
Chaenomeles, e.g. flowering quince
A61K 36/734
. . . .
Crataegus (hawthorn)
A61K 36/736
. . . .
Prunus, e.g. plum, cherry, peach, apricot or almond
A61K 36/738
. . . .
Rosa (rose)
A61K 36/739
. . . .
Sanguisorba (burnet)
Collapse
A61K 36/74
. . .
Rubiaceae( Madder family )
A61K 36/744
. . . .
Gardenia
A61K 36/746
. . . .
Morinda
A61K 36/748
. . . .
Oldenlandia or Hedyotis
Collapse
A61K 36/75
. . .
Rutaceae( Rue family )
A61K 36/752
. . . .
Citrus, e.g. lime, orange or lemon
A61K 36/754
. . . .
Evodia
A61K 36/756
. . . .
Phellodendron, e.g. corktree
A61K 36/758
. . . .
Zanthoxylum, e.g. pricklyash
A61K 36/76
. . .
Salicaceae( Willow family ), e.g. poplar
A61K 36/77
. . .
Sapindaceae( Soapberry family ), e.g. lychee or soapberry
A61K 36/78
. . .
Saururaceae( Lizard's-tail family )
A61K 36/79
. . .
Schisandraceae( Schisandra family )
Collapse
A61K 36/80
. . .
Scrophulariaceae( Figwort family )
A61K 36/804
. . . .
Rehmannia
A61K 36/808
. . . .
Scrophularia (figwort)
Collapse
A61K 36/81
. . .
Solanaceae( Potato family ), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
A61K 36/815
. . . .
Lycium (desert-thorn)
A61K 36/82
. . .
Theaceae( Tea family ), e.g. camellia
Collapse
A61K 36/83
. . .
Thymelaeaceae( Mezereum family ), e.g. leatherwood or false ohelo
A61K 36/835
. . . .
Aquilaria
A61K 36/84
. . .
Valerianaceae( Valerian family ), e.g. valerian
Collapse
A61K 36/85
. . .
Verbenaceae( Verbena family )
A61K 36/855
. . . .
Clerodendrum, e.g. glorybower
A61K 36/86
. . .
Violaceae( Violet family )
A61K 36/87
. . .
Vitaceae or Ampelidaceae( Vine or Grape family ), e.g. wine grapes, muscadine or peppervine
Collapse
A61K 36/88
. .
Liliopsida (monocotyledons)
A61K 36/882
. . .
Acoraceae( Calamus family ), e.g. sweetflag or Acorus calamus
A61K 36/884
. . .
Alismataceae( Water-plantain family )
A61K 36/886
. . .
Aloeaceae( Aloe family ), e.g. aloe vera
Collapse
A61K 36/888
. . .
Araceae( Arum family ), e.g. caladium, calla lily or skunk cabbage
A61K 36/8884
. . . .
Arisaema, e.g. Jack in the pulpit
A61K 36/8888
. . . .
Pinellia
Collapse
A61K 36/889
. . .
Arecaceae, Palmae or Palmaceae( Palm family ), e.g. date or coconut palm or palmetto
A61K 36/8895
. . . .
Calamus, e.g. rattan
Collapse
A61K 36/89
. . .
Cyperaceae( Sedge family )
A61K 36/8905
. . . .
Cyperus (flatsedge)
Collapse
A61K 36/894
. . .
Dioscoreaceae( Yam family )
A61K 36/8945
. . . .
Dioscorea, e.g. yam, Chinese yam or water yam
Collapse
A61K 36/896
. . .
Liliaceae( Lily family ), e.g. daylily, plantain lily, Hyacinth or narcissus
A61K 36/8962
. . . .
Allium, e.g. garden onion, leek, garlic or chives
A61K 36/8964
. . . .
Anemarrhena
A61K 36/8965
. . . .
Asparagus, e.g. garden asparagus or asparagus fern
A61K 36/8966
. . . .
Fritillaria, e.g. checker lily or mission bells
A61K 36/8967
. . . .
Lilium, e.g. tiger lily or Easter lily
A61K 36/8968
. . . .
Ophiopogon (Lilyturf)
A61K 36/8969
. . . .
Polygonatum( Solomon's seal )
Collapse
A61K 36/898
. . .
Orchidaceae( Orchid family )
A61K 36/8984
. . . .
Dendrobium
A61K 36/8988
. . . .
Gastrodia
Collapse
A61K 36/899
. . .
Poaceae or Gramineae( Grass family ), e.g. bamboo, corn or sugar cane
A61K 36/8994
. . . .
Coix( Job's tears )
A61K 36/8998
. . . .
Hordeum (barley)
A61K 36/90
. . .
Smilacaceae( Catbrier family ), e.g. greenbrier or sarsaparilla
A61K 36/902
. . .
Sparganiaceae( Bur-reed family )
A61K 36/904
. . .
Stemonaceae( Stemona family ), e.g. croomia
Collapse
A61K 36/906
. . .
Zingiberaceae( Ginger family )
A61K 36/9062
. . . .
Alpinia, e.g. red ginger or galangal
A61K 36/9064
. . . .
Amomum, e.g. round cardamom
A61K 36/9066
. . . .
Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
A61K 36/9068
. . . .
Zingiber, e.g. garden ginger
Collapse
Medicinal preparations containing peptides( peptides containing beta-lactam rings A61K 31/00 ; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K 31/00 ; ergot alkaloids of the cyclic peptide type A61K 31/48 ; containing macromolecular compounds having statistically distributed amino acid units A61K 31/74 ; medicinal preparations containing antigens or antibodies A61K 39/00 ; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K 47/00 )
NOTE
-
The terms or expressions used in this group follow exactly the definitions given in Note (1) following the title of subclass C07K .

Preparations containing fragments of peptides or peptides modified by removal or addition of amino acids, by substitution of amino acids by others, or by combination of these modifications are classified as the preparations containing parent peptides. However, preparations containing fragments of peptides having only four or less amino acids are also classified in groups A61K 38/05 to A61K 38/07 .

Preparations containing peptides prepared by recombinant DNA technology are not classified according to the host, but according to the original peptide expressed, e.g. preparations containing HIV peptide expressed in E. coli are classified with the preparations containing HIV peptides.

This group covers also medicinal preparation containing DNA or RNA encoding for peptides as active ingredient.

Documents relating to new peptides, e.g. enzymes, or new DNA or RNA encoding for peptides and their use in medicinal preparations are classified in subclass C07K or in group C12N 9/00 according to the peptides, with the appropriate indexing codes relating to their medical uses.


A61K 38/005
.
{
Enzyme inhibitors( protease inhibitors A61K 38/55 )
}
Collapse
A61K 38/01
.
Hydrolysed proteins ; Derivatives thereof
A61K 38/011
. .
{
from plants
}
Collapse
A61K 38/012
. .
{
from animals
}
Collapse
A61K 38/014
. . .
{
from connective tissue peptides, e.g. gelatin, collagen
}
A61K 38/015
. . . .
{
from keratin
}
A61K 38/017
. . .
{
from blood
}
A61K 38/018
. . .
{
from milk
}
A61K 38/02
.
Peptides of undefined number of amino acids ; Derivatives thereof
A61K 38/03
.
Peptides having up to 20 amino acids in an undefined or only partially defined sequence ; Derivatives thereof
Collapse
A61K 38/04
.
Peptides having up to 20 amino acids in a fully defined sequence ; Derivatives thereof(
{
enzyme inhibitors A61K 38/005
}
; gastrins
{
A61K 38/2207
}
somatostatins A61K 38/31 , melanotropins A61K 38/34 ;
{
protease inhibitors A61K 38/55
}
)
A61K 38/043
. .
{
Kallidins; Bradykinins; Related peptides
}
A61K 38/046
. .
{
Tachykinins, e.g. eledoisins, substance P; Related peptides
}
A61K 38/05
. .
Dipeptides
Collapse
A61K 38/06
. .
Tripeptides
A61K 38/063
. . .
{
Glutathione
}
A61K 38/066
. . .
{
TRH, thyroliberin, thyrotropin releasing hormone
}
A61K 38/07
. .
Tetrapeptides
Collapse
A61K 38/08
. .
Peptides having 5 to 11 amino acids
{
( A61K 38/043 to A61K 38/046 take precedence )
}
A61K 38/085
. . .
{
Angiotensins
}
A61K 38/09
. . .
Luteinising hormone-releasing hormone (LHRH)
{
i.e. Gonadotropin-releasing hormone (GnRH)
}
; Related peptides
Collapse
A61K 38/10
. .
Peptides having 12 to 20 amino acids
{
( A61K 38/043 to A61K 38/046 take precedence )
}
A61K 38/105
. . .
{
Bombesin; Related peptides
}
A61K 38/11
. . .
Oxytocins ; Vasopressins ; Related peptides
Collapse
A61K 38/12
. .
Cyclic peptides
{
, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C( A61K 38/043 to A61K 38/046 take precedence )
}
A61K 38/13
. . .
Cyclosporins
A61K 38/14
. .
Peptides containing saccharide radicals ; Derivatives thereof
{
e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
}
A61K 38/15
. .
Depsipeptides ; Derivatives thereof
Collapse
A61K 38/16
.
Peptides having more than 20 amino acids ; Gastrins ; Somatostatins ; Melanotropins ; Derivatives thereof
{
( enzyme inhibitors A61K 38/005 )
}
A61K 38/162
. .
{
from virus
}
Collapse
A61K 38/164
. .
{
from bacteria
}
A61K 38/166
. . .
{
Streptokinase
}
A61K 38/168
. .
{
from plants
}
Collapse
A61K 38/17
. .
from animals ; from humans
{
( enzyme inhibitors A61K 38/005 )
}
Collapse
A61K 38/1703
. . .
{
from vertebrates( A61K 38/1767 takes precedence )
}
A61K 38/1706
. . . .
{
from fish
}
Collapse
A61K 38/1709
. . . .
{
from mammals
}
Collapse
A61K 38/1712
. . . . .
{
Not used, see subgroup
}
A61K 38/1716
. . . . . .
{
Amyloid plaque core protein
}
A61K 38/1719
. . . . . .
{
Muscle proteins, e.g. myosin, actin
}
A61K 38/1722
. . . . . .
{
Plasma globulins, lactoglobulin
}
A61K 38/1725
. . . . . .
{
Complement proteins, e.g. anaphylatoxin, C3a, C5a
}
A61K 38/1729
. . . . . .
{
Cationic antimicrobial peptides, e.g. defensins
}
A61K 38/1732
. . . . . .
{
Lectins
}
A61K 38/1735
. . . . . .
{
Mucins, e.g. human intestinal mucin
}
A61K 38/1738
. . . . . .
{
Calcium binding proteins, e.g. calmodulin
}
A61K 38/1741
. . . . . .
{
alpha-Glycoproteins
}
A61K 38/1745
. . . . . .
{
C-reactive protein
}
A61K 38/1748
. . . . . .
{
Keratin; Cytokeratin
}
A61K 38/1751
. . . . . .
{
Bactericidal/permeability-increasing protein (BPI)
}
A61K 38/1754
. . . . . .
{
Insulin-like growth factor binding protein
}
A61K 38/1758
. . . . . .
{
p53
}
A61K 38/1761
. . . . . .
{
Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)( BI; bax-I ), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis (IAP), Bcl-2
}
A61K 38/1764
. . . . . .
{
Tumor specific antigens; Tumor rejection antigen precursors (TRAP), e.g. MAGE
}
A61K 38/1767
. . .
{
from invertebrates
}
Collapse
A61K 38/177
. . .
{
Receptors; Cell surface antigens; Cell surface determinants
}
A61K 38/1774
. . . .
{
Immunoglobulin superfamily( e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules )
}
A61K 38/1777
. . . .
{
Integrin superfamily
}
A61K 38/178
. . . .
{
Lectin superfamily, e.g. selectins
}
A61K 38/1783
. . . .
{
Nuclear receptors, e.g. retinoic acid receptor (RAR), RXR, nuclear orphan receptors
}
A61K 38/1787
. . . .
{
for neuromediators, e.g. serotonin receptor, dopamine receptor
}
A61K 38/179
. . . .
{
for growth factors; for growth regulators
}
A61K 38/1793
. . . .
{
for cytokines; for lymphokines; for interferons
}
A61K 38/1796
. . . .
{
for hormones( for neuromediators A61K 38/1787 )
}
Collapse
A61K 38/18
. . .
Growth factors ; Growth regulators
A61K 38/1808
. . . .
{
Epidermal growth factor (EGF) urogastrone
}
A61K 38/1816
. . . .
{
Erythropoietin (EPO)
}
A61K 38/1825
. . . .
{
Fibroblast growth factor (FGF)
}
A61K 38/1833
. . . .
{
Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
}
A61K 38/1841
. . . .
{
Transforming growth factor (TGF)
}
A61K 38/185
. . . .
{
Nerve growth factor (NGF); Brain derived neurotrophic factor (BDNF); Ciliary neurotrophic factor (CNTF); Glial derived neurotrophic factor (GDNF); Neurotrophins, e.g. NT-3
}
Collapse
A61K 38/1858
. . . .
{
Platelet-derived growth factor (PDGF)
}
A61K 38/1866
. . . . .
{
Vascular endothelial growth factor (VEGF)
}
A61K 38/1875
. . . .
{
Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
}
A61K 38/1883
. . . .
{
Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
}
A61K 38/1891
. . . .
[Angiogenesic factors ; Angiogenin]
Collapse
A61K 38/19
. . .
Cytokines ; Lymphokines ; Interferons
A61K 38/191
. . . .
{
Tumor necrosis factors [TNF
}
, e.g. lymphotoxin [LT] i.e. TNF-beta]
A61K 38/193
. . . .
{
Colony stimulating factors [CSF
}
]
A61K 38/195
. . . .
{
Chemokines, e.g. RANTES
}
A61K 38/196
. . . .
{
Thrombopoietin
}
Collapse
A61K 38/20
. . . .
Interleukins [IL]
A61K 38/2006
. . . . .
{
IL-1
}
A61K 38/2013
. . . . .
{
IL-2
}
A61K 38/202
. . . . .
{
IL-3
}
A61K 38/2026
. . . . .
{
IL-4
}
A61K 38/2033
. . . . .
{
IL-5
}
A61K 38/204
. . . . .
{
IL-6
}
A61K 38/2046
. . . . .
{
IL-7
}
A61K 38/2053
. . . . .
{
IL-8
}
A61K 38/206
. . . . .
{
IL-9
}
A61K 38/2066
. . . . .
{
IL-10
}
A61K 38/2073
. . . . .
{
IL-11
}
A61K 38/208
. . . . .
{
IL-12
}
A61K 38/2086
. . . . .
{
IL-13 to IL-16
}
A61K 38/2093
. . . . .
{
Leukaemia inhibitory factor (LIF)
}
Collapse
A61K 38/21
. . . .
Interferons
{
(IFN)
}
A61K 38/212
. . . . .
{
IFN-alpha
}
A61K 38/215
. . . . .
{
IFN-beta
}
A61K 38/217
. . . . .
{
IFN-gamma
}
Collapse
A61K 38/22
. . .
Hormones( derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K 38/33 , e.g. corticotropin A61K 38/35 )
A61K 38/2207
. . . .
{
Gastrins; Cholecystokinins [CCK
}
]
A61K 38/2214
. . . .
{
Motilins
}
A61K 38/2221
. . . .
{
Relaxins
}
A61K 38/2228
. . . .
{
Corticotropin releasing factor (CRF) (Urotensin)
}
A61K 38/2235
. . . .
{
Secretins
}
A61K 38/2242
. . . .
{
Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein (ANP); Cardionatrin, Cardiodilatin
}
A61K 38/225
. . . .
{
Calcitonin gene related peptide
}
A61K 38/2257
. . . .
{
Prolactin
}
A61K 38/2264
. . . .
{
Obesity-gene products, e.g. leptin
}
A61K 38/2271
. . . .
{
Neuropeptide Y
}
A61K 38/2278
. . . .
{
Vasoactive intestinal peptide (VIP); Related peptides( e.g. Exendin )
}
A61K 38/2285
. . . .
{
Endothelin, vasoactive intestinal contractor (VIC)
}
A61K 38/2292
. . . .
{
Thymosin; Related peptides
}
A61K 38/23
. . . .
Calcitonins
A61K 38/24
. . . .
Follicle-stimulating hormone (FSH) ; Chorionic gonadotropins, e.g. HCG ; Luteinising hormone (LH) ; Thyroid-stimulating hormone (TSH)
A61K 38/25
. . . .
Growth hormone-releasing factor (GH-RF) (Somatoliberin)
A61K 38/26
. . . .
Glucagons
A61K 38/27
. . . .
Growth hormone (GH) (Somatotropin)
A61K 38/28
. . . .
Insulins
A61K 38/29
. . . .
Parathyroid hormone (parathormone) ; Parathyroid hormone-related peptides
A61K 38/30
. . . .
Insulin-like growth factors (somatomedins), e.g. IGF-1, IGF-2
{
insulin-like growth factor binding protein A61K 38/1754
}
A61K 38/31
. . . .
Somatostatins
A61K 38/32
. . . .
Thymopoietins
Collapse
A61K 38/33
. . .
derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
A61K 38/34
. . . .
Melanocyte stimulating hormone (MSH), e.g. alpha- or beta-melanotropin
A61K 38/35
. . . .
Corticotropin (ACTH)
Collapse
A61K 38/36
. . .
Blood coagulation or fibrinolysis factors
A61K 38/363
. . . .
{
Fibrinogen
}
A61K 38/366
. . . .
{
Thrombomodulin
}
A61K 38/37
. . . .
Factors VIII
Collapse
A61K 38/38
. . .
Albumins
A61K 38/385
. . . .
{
Serum albumin
}
A61K 38/39
. . .
Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin (CIG)
A61K 38/395
. . .
{
Alveolar surfactant peptides; Pulmonary surfactant peptides
}
A61K 38/40
. . .
Transferrins, e.g. lactoferrins, ovotransferrins
Collapse
A61K 38/41
. .
Porphyrin- or corrin-ring-containing peptides
A61K 38/415
. . .
{
Cytochromes
}
A61K 38/42
. . .
Haemoglobins ; Myoglobins
Collapse
A61K 38/43
. .
Enzymes ; Proenzymes ; Derivatives thereof
NOTE
-
In this group, 1. proenzymes are classified with the corresponding enzymes; 2. enzymes are generally categorised according to the "Nomenclature and Classification of Enzymes" of the International Commission of Enzymes. Where appropriate, this designation appears in the subgroups below in parenthesis. 3. the specific enzyme(s) used are additionally classified in C12Y .

Collapse
A61K 38/44
. . .
Oxidoreductases (1)
A61K 38/443
. . . .
{
acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
}
A61K 38/446
. . . .
{
Superoxide dismutase (1.15)
}
A61K 38/45
. . .
Transferases (2)
Collapse
A61K 38/46
. . .
Hydrolases (3)
A61K 38/465
. . . .
{
acting on ester bonds (3.1), e.g. lipases, ribonucleases
}
A61K 38/47
. . . .
acting on glycosyl compounds (3.2), e.g. cellulases, lactases
Collapse
A61K 38/48
. . . .
acting on peptide bonds (3.4)
A61K 38/4806
. . . . .
{
from animals other than mammals, e.g. snakes
}
A61K 38/4813
. . . . .
{
Exopeptidases( 3.4.11. to 3.4.19 )
}
Collapse
A61K 38/482
. . . . .
{
Serine endopeptidases (3.4.21)
}
A61K 38/4826
. . . . . .
{
Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
}
A61K 38/4833
. . . . . .
{
Thrombin (3.4.21.5)
}
A61K 38/484
. . . . . .
{
Plasmin (3.4.21.7)
}
A61K 38/4846
. . . . . .
{
Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
}
A61K 38/4853
. . . . . .
{
Kallikrein( 3.4.21.34 or 3.4.21.35 )
}
A61K 38/486
. . . . . .
{
Elastase( 3.4.21.36 or 3.4.21.37 )
}
A61K 38/4866
. . . . . .
{
Protein C (3.4.21.69)
}
A61K 38/4873
. . . . .
{
Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
}
A61K 38/488
. . . . .
{
Aspartic endopeptidases (3.4.23), e.g. pepsin, chymosin, renin, cathepsin E
}
Collapse
A61K 38/4886
. . . . .
{
Metalloendopeptidases (3.4.24), e.g. collagenase
}
A61K 38/4893
. . . . . .
{
Botulinum neurotoxin (3.4.24.69)
}
A61K 38/49
. . . . .
Urokinase ; Tissue plasminogen activator
A61K 38/50
. . . .
acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
A61K 38/51
. . .
Lyases (4)
A61K 38/52
. . .
Isomerases (5)
A61K 38/53
. . .
Ligases (6)
A61K 38/54
. . .
Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K 38/44 to A61K 38/46 or A61K 38/51 to A61K 38/53
Collapse
A61K 38/55
. .
Protease inhibitors
A61K 38/553
. . .
{
Renin inhibitors
}
A61K 38/556
. . .
{
Angiotensin converting enzyme inhibitors
}
A61K 38/56
. . .
from plants
Collapse
A61K 38/57
. . .
from animals ; from humans
{
( A61K 38/553 , A61K 38/556 take precedence )
}
A61K 38/58
. . . .
from leeches, e.g. hirudin, eglin
Collapse
Medicinal preparations containing antigens or antibodies( materials for immunoassay G01N 33/53 )
NOTE
-
Groups A61K 39/002 to A61K 39/295 cover preparations containing protozoa, bacteria, viruses, or subunits thereof, e.g. membrane parts.

Preparation of antigen or antibody compositions is also classified in subclass C12N , if the step of cultivating the micro-organism is of interest.

Documents relating to new peptides, e.g. enzymes, or new DNA or RNA encoding for peptides and their use in medicinal preparations are classified in subclass C07K or in group C12N 9/00 according to the peptides, with the appropriate indexing codes relating to their medical uses.

Documents relating to antibodies or DNA or RNA encoding for antibodies and their use in medicinal preparations are classified in group C07K 16/00 or in group C12N 9/0002 according to the antibodies, with the appropriate indexing codes relating to their medical uses.

Documents relating to new therapeutical uses of antibodies or DNA or RNA encoding for antibodies are classified in group C07K 16/00 or in group C12N 9/0002 according to the antibodies, with the appropriate indexing codes relating to their medical uses.

Documents relating to medicinal preparations containing different antibodies as active ingredients are classified in group C07K 16/00 according to the different active antibodies, with the appropriate indexing codes relating to their medical uses. However, documents relating to medicinal preparations containing antibodies and other compounds as active ingredients are classified in groups A61K 39/395 to A61K 39/42 , in association with symbol A61K 2300/00 in Combination Sets.


A61K 39/0001
.
{
Archaeal antigens
}
A61K 39/0002
.
{
Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
}
A61K 39/0003
.
{
Invertebrate antigens
}
Collapse
A61K 39/0005
.
{
Vertebrate antigens( from snakes A61K 39/38 )
}
A61K 39/0006
. .
{
Contraceptive vaccins; Vaccines against sex hormones
}
A61K 39/0007
. .
{
Nervous system antigens; Prions
}
A61K 39/0008
. .
{
Antigens related to auto-immune diseases; Preparations to induce self-tolerance
}
A61K 39/001
. .
{
Preparations to induce tolerance to non-self, e.g. prior to transplantation
}
A61K 39/0011
. .
{
Cancer antigens
}
A61K 39/0012
. .
{
Lipids; Lipoproteins
}
A61K 39/0013
.
{
Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
}
A61K 39/0015
.
{
Combination vaccines based on measles-mumps-rubella
}
Collapse
A61K 39/0016
.
{
Combination vaccines based on diphtheria-tetanus-pertussis
}
A61K 39/0017
. .
{
Combination vaccines based on whole cell diphtheria-tetanus-pertussis
}
A61K 39/0018
. .
{
Combination vaccines based on acellular diphtheria-tetanus-pertussis
}
Collapse
A61K 39/002
.
Protozoa antigens
A61K 39/005
. .
Trypanosoma antigens
A61K 39/008
. .
Leishmania antigens
A61K 39/012
. .
Coccidia antigens
Collapse
A61K 39/015
. .
Hemosporidia antigens, e.g. Plasmodium antigens
A61K 39/018
. . .
Babesia antigens, e.g. Theileria antigens
Collapse
A61K 39/02
.
Bacterial antigens
A61K 39/0208
. .
{
Specific bacteria not otherwise provided for
}
A61K 39/0216
. .
{
Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
}
A61K 39/0225
. .
{
Spirochetes, e.g. Treponema, Leptospira, Borrelia
}
A61K 39/0233
. .
{
Rickettsiales, e.g. Anaplasma
}
A61K 39/0241
. .
{
Mollicutes, e.g. Mycoplasma, Erysipelothrix
}
Collapse
A61K 39/025
. .
{
Enterobacteriales, e.g. Enterobacter
}
A61K 39/0258
. . .
{
Escherichia
}
A61K 39/0266
. . .
{
Klebsiella
}
A61K 39/0275
. . .
{
Salmonella
}
A61K 39/0283
. . .
{
Shigella
}
A61K 39/0291
. . .
{
Yersinia
}
A61K 39/04
. .
Mycobacterium, e.g. Mycobacterium tuberculosis
A61K 39/05
. .
{
Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella
}
, Corynebacterium ; Propionibacterium
{
( Mycobacterium A61K 39/04 )
}
A61K 39/07
. .
Bacillus
A61K 39/08
. .
Clostridium, e.g. Clostridium tetani
A61K 39/085
. .
Staphylococcus
Collapse
A61K 39/09
. .
{
Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus
}
, streptococcus
A61K 39/092
. . .
{
Streptococcus
}
A61K 39/095
. .
Neisseria
A61K 39/098
. .
{
Brucella
}
A61K 39/099
. .
{
Bordetella
}
A61K 2039/10
. .
{
Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
}
A61K 39/102
. .
{
Pasteurellales, e.g. Actinobacillus
}
, Pasteurella ; Haemophilus
Collapse
A61K 39/104
. .
{
Pseudomonadales, e.g.
}
Pseudomonas
A61K 39/1045
. . .
{
Moraxella
}
A61K 39/105
. .
{
Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
}
A61K 2039/106
. .
{
Vibrio; Campylobacter; Not used, see subgroups
}
A61K 39/107
. .
{
Vibrio
}
A61K 39/114
. .
Fusobacterium
A61K 39/116
. .
Polyvalent bacterial antigens
WARNING
-
This group is no longer used for the classification of new documents as from April 1, 2012. The backlog of this group is being continuously reclassified to subgroups of A61K 39/0016 and of A61K 39/02

A61K 39/118
.
Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
Collapse
A61K 39/12
.
Viral antigens
Collapse
A61K 39/125
. .
Picornaviridae, e.g. calicivirus
A61K 39/13
. . .
Poliovirus
A61K 39/135
. . .
Foot- and mouth-disease virus
A61K 39/145
. .
Orthomyxoviridae, e.g. influenza virus
A61K 39/15
. .
Reoviridae, e.g. calf diarrhea virus
Collapse
A61K 39/155
. .
Paramyxoviridae, e.g. parainfluenza virus
A61K 39/165
. . .
Mumps or measles virus
A61K 39/17
. . .
Newcastle disease virus
A61K 39/175
. . .
Canine distemper virus
A61K 39/187
. .
Hog cholera virus
A61K 39/193
. .
Equine encephalomyelitis virus
A61K 39/20
. .
Rubella virus
A61K 39/205
. .
Rhabdoviridae, e.g. rabies virus
A61K 39/21
. .
Retroviridae, e.g. equine infectious anemia virus
Collapse
A61K 39/215
. .
Coronaviradae, e.g. avian infectious bronchitis virus
A61K 39/225
. . .
Porcine transmissible gastroenteritis virus
A61K 39/23
. .
Parvoviridae, e.g. feline panleukopenia virus
A61K 39/235
. .
Adenoviridae
Collapse
A61K 39/245
. .
Herpetoviridae, e.g. herpes simplex virus
A61K 39/25
. . .
Varicella-zoster virus
A61K 39/255
. . .
Marek`s disease virus
A61K 39/265
. . .
Infectious rhinotracheitis virus
A61K 39/27
. . .
Equine rhinopneumonitis virus
Collapse
A61K 39/275
. .
Poxviridae, e.g. avipoxvirus
A61K 39/285
. . .
Vaccinia virus or variola virus
Collapse
A61K 39/29
. .
Hepatitis virus
A61K 39/292
. . .
{
Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
}
A61K 39/295
. .
Polyvalent viral antigens( vaccinia virus or variola virus A61K 39/285 ) ; Mixtures of viral and bacterial antigens
WARNING
-
This group is no longer used for the classification of new documents as from April 1, 2012. The backlog of this group is being continuously reclassified to A61K39/00M, to subgroups of A61K 39/0016 and of A61K 39/12

Collapse
A61K 39/35
.
Allergens
A61K 39/36
. .
from pollen
A61K 39/38
.
Antigens from snakes
A61K 39/385
.
Haptens or antigens, bound to carriers
A61K 39/39
.
characterised by the immunostimulating additives, e.g. chemical adjuvants
Collapse
A61K 39/395
.
Antibodies( agglutinins A61K 38/36 ;
{
as drug carriers A61K 47/48
}
)
; Immunoglobulins ; Immune serum, e.g. antilymphocytic serum
A61K 39/39508
. .
{
from milk, i.e. lactoglobulins
}
Collapse
A61K 39/39516
. .
{
from serum, plasma
}
A61K 39/39525
. . .
{
Purification
}
Collapse
A61K 39/39533
. .
{
against materials from animals
}
A61K 39/39541
. . .
{
against normal tissues, cells
}
A61K 39/3955
. . .
{
against proteinaceous materials, e.g. enzymes, hormones, lymphokines
}
A61K 39/39558
. . .
{
against tumor tissues, cells, antigens
}
A61K 39/39566
. . .
{
against immunoglobulins, e.g. anti-idiotypic antibodies
}
A61K 39/39575
. .
{
against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
}
A61K 39/39583
. .
{
against materials not provided for elsewhere, e.g. haptens, coenzymes
}
A61K 39/39591
. .
{
Stabilisation, fragmentation
}
A61K 39/40
. .
bacterial
A61K 39/42
. .
viral
A61K 39/44
. .
Antibodies bound to carriers
Collapse
A61K 2039/505
.
{
comprising antibodies
}
A61K 2039/507
. .
{
Comprising a combination of two or more separate antibodies
}
Collapse
A61K 2039/51
.
{
comprising whole cells, viruses or DNA/RNA
}
Collapse
A61K 2039/515
. .
{
Animal cells
}
A61K 2039/5152
. . .
{
Tumor cells
}
A61K 2039/5154
. . .
{
Antigen presenting cells [APCs], e.g. dendritic cells, macrophages
}
A61K 2039/5156
. . .
{
expressing foreign proteins
}
A61K 2039/5158
. . .
{
Antigen-pulsed cells e.g. T-cells
}
A61K 2039/517
. .
{
Plant cells
}
Collapse
A61K 2039/52
. .
{
Bacterial cells; Fungal cells; Protozoal cells
}
A61K 2039/521
. . .
{
inactivated (killed)
}
A61K 2039/522
. . .
{
avirulent or attenuated
}
A61K 2039/523
. . .
{
expressing foreign proteins
}
Collapse
A61K 2039/525
. .
{
Virus
}
A61K 2039/5252
. . .
{
inactivated (killed)
}
A61K 2039/5254
. . .
{
avirulent or attenuated
}
A61K 2039/5256
. . .
{
expressing foreign proteins
}
A61K 2039/5258
. . .
{
Virus-like particles
}
A61K 2039/53
. .
{
DNA (RNA) vaccination
}
Collapse
A61K 2039/54
.
{
characterised by the route of administration
}
Collapse
A61K 2039/541
. .
{
Mucosal route
}
A61K 2039/542
. . .
{
oral/gastrointestinal
}
A61K 2039/543
. . .
{
intranasal
}
A61K 2039/544
. . .
{
to the airways( intranasal A61K 2039/543 )
}
A61K 2039/545
.
{
characterised by the dose, timing or administration schedule
}
Collapse
A61K 2039/55
.
{
characterised by the host/recipient, e.g. newborn with maternal antibodies
}
A61K 2039/552
. .
{
Veterinary vaccine
}
Collapse
A61K 2039/555
.
{
characterised by a specific combination antigen/adjuvant
}
A61K 2039/55505
. .
{
Inorganic adjuvants
}
Collapse
A61K 2039/55511
. .
{
Organic adjuvants
}
A61K 2039/55516
. . .
{
Proteins; Peptides
}
Collapse
A61K 2039/55522
. . .
{
Cytokines; Lymphokines; Interferons
}
Collapse
A61K 2039/55527
. . . .
{
Interleukins
}
A61K 2039/55533
. . . . .
{
IL-2
}
A61K 2039/55538
. . . . .
{
IL-12
}
A61K 2039/55544
. . .
{
Bacterial toxins
}
A61K 2039/5555
. . .
{
Muramyl dipeptides
}
A61K 2039/55555
. . .
{
Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
}
A61K 2039/55561
. . .
{
CpG containing adjuvants; Oligonucleotide containing adjuvants
}
A61K 2039/55566
. . .
{
Emulsions, e.g. Freund's adjuvant, MF59
}
A61K 2039/55572
. . .
{
Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
}
A61K 2039/55577
. . .
{
Saponins; Quil A; QS21; ISCOMS
}
A61K 2039/55583
. . .
{
Polysaccharides
}
Collapse
A61K 2039/55588
. .
{
Adjuvants of undefined constitution
}
A61K 2039/55594
. . .
{
from bacteria
}
Collapse
A61K 2039/57
.
{
characterised by the type of response, e.g. Th1, Th2
}
A61K 2039/572
. .
{
cytotoxic response
}
A61K 2039/575
. .
{
humoral response
}
A61K 2039/577
. .
{
tolerising response
}
Collapse
A61K 2039/58
.
{
raising an immune response against a target which is not the antigen used for immunisation
}
A61K 2039/585
. .
{
wherein the target is cancer
}
Collapse
A61K 2039/60
.
{
characteristics by the carrier linked to the antigen
}
A61K 2039/6006
. .
{
Cells( recombinantly expressing antigens A61K 2039/5156 , A61K 2039/523 )
}
A61K 2039/6012
. .
{
Haptens, e.g. di- or trinitrophenyl( DNP, TNP )
}
A61K 2039/6018
. .
{
Lipids, e.g. in lipopeptides
}
A61K 2039/6025
. .
{
Nucleotides
}
Collapse
A61K 2039/6031
. .
{
Proteins
}
A61K 2039/6037
. . .
{
Bacterial toxins, e.g. diphteria toxoid (DT), tetanus toxoid (TT)
}
A61K 2039/6043
. . .
{
Heat shock proteins
}
A61K 2039/605
. . .
{
MHC molecules or ligands thereof
}
A61K 2039/6056
. . .
{
Antibodies
}
A61K 2039/6062
. . .
{
Muramyl peptides
}
A61K 2039/6068
. . .
{
Other bacterial proteins, e.g. OMP
}
A61K 2039/6075
. . .
{
Viral proteins
}
A61K 2039/6081
. . .
{
Albumin; Keyhole limpet haemocyanin (KLH)
}
A61K 2039/6087
. .
{
Polysaccharides; Lipopolysaccharides (LPS)
}
A61K 2039/6093
. .
{
Synthetic polymers, e.g. polyethyleneglycol (PEG), Polymers or copolymers of (D) glutamate and (D) lysine
}
Collapse
A61K 2039/62
.
{
characterised by the link between antigen and carrier
}
A61K 2039/622
. .
{
non-covalent binding
}
A61K 2039/625
. .
{
binding through the biotin-streptavidin system or similar
}
A61K 2039/627
. .
{
characterised by the linker
}
Collapse
A61K 2039/64
.
{
characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
}
A61K 2039/645
. .
{
Dendrimers; Multiple antigen peptides
}
A61K 2039/70
.
{
Multivalent vaccine
}
Collapse
Medicinal preparations obtained by treating materials with wave energy or particle radiation;
{
Therapies using these preparations
}
( A61K 31/59 takes precedence; generation of ultrasonic waves B06B ; electric discharge tubes H01J )
A61K 41/0004
.
{
Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
}
Collapse
A61K 41/0009
.
{
Inactivation or decontamination of a medicinal preparation prior to administration to the animal or human, e.g. : inactivation of viruses or bacteria for vaccines, sterilisation by electromagnetic radiation
}
NOTE
-
See A61K 41/0019 for the specific method; see A61L 2/0029 if the invention lies in the method of sterilization of the medicinal preparation rather than the sterilized medicinal preparation

A61K 41/0014
. .
{
by ultrasonic waves
}
A61K 41/0019
. .
{
by UV, IR, Rx or gamma rays
}
A61K 41/0023
.
{
Agression treatment or altering
}
NOTE
-
This groups covers aggression treatment or altering - of a medicinal preparation prior to administration to the human/animal, e.g. altering a binding specificity of a monoclonal antibody used in a medicinal agent with an oxidizing agent or an electric potential; - of a tissue/organ prior to graft, e.g. destroying immunodominant epitopes; - the permeability of cell membranes or biological barriers in vivo, e.g. by ultrasound, prior to the administration of a medicinal preparation to the animal/human; - for inducing the production of stress response proteins or heat shock proteins in order to reduce subsequent response to injuries

Collapse
A61K 41/0028
.
{
Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation; e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
}
A61K 41/0033
. .
{
Sonodynamic cancer therapy with sonochemically active agents or sonosensitizers, having their cytotoxic effects enhanced through application of ultrasounds( ultrasound therapy per se A61N 7/00 )
}
A61K 41/0038
.
{
Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy( radiotherapy per se A61N 5/10 )
}
A61K 41/0042
.
{
Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
}
A61K 41/0047
.
{
Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
}
NOTE
-
To be classified in A61K 9/0009 when it is in relation to the galenic form]

A61K 41/0052
.
{
Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
}
NOTE
-
simple magnetic guidance of drugs in vivo is to be classified in A61K 41/00 , and in A61K 47/4893

Collapse
A61K 41/0057
.
{
Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
}
A61K 41/0061
. .
{
5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
}
A61K 41/0066
. .
{
Psoralene-activated UV-A photochemotherapy (PUVA-therapy), e.g. for treatment of psoriasis or eczema, extracorporeal photopheresis with psoralens or fucocoumarins
}
A61K 41/0071
. .
{
PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
}
A61K 41/0076
. .
{
PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
}
A61K 41/008
. .
{
Two-Photon or Multi-Photon PDT, e.g. with upconverting dyes or photosensitisers
}
A61K 41/0085
.
{
Mossbauer effect therapy based on mossbauer effect of a material, i.e. re-emission of gamma rays after absorption of gamma rays by the material; selective radiation therapy, i.e. involving re-emission of ionizing radiation upon exposure to a first ionizing radiation
}
Collapse
A61K 41/009
.
{
Neutron capture therapy, e.g. using uranium or non-boron material
}
A61K 41/0095
. .
{
Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins
}
Collapse
A61K 45/00
Medicinal preparations containing active ingredients not provided for in groups A61K 31/00 to A61K 41/00
A61K 45/05
.
Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
.
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Collapse
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
A61K 47/02
.
Inorganic compounds
Collapse
A61K 47/06
.
Organic compounds,
{
e.g. mineral oil, petrolatum, synthetic polyolefins
}
Collapse
A61K 47/08
. .
containing oxygen,
{
e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
}
A61K 47/10
. . .
Alcohols ; Phenols ; Salts thereof,
{
e.g. glycerol; Polyethylene glycol( PEG ); Poloxamers; PEG/POE alkyl ethers( sugar alcohols A61K 47/26 ; copolymers containing polyalkylene glycol or poloxamer A61K 47/34 )
}
A61K 47/12
. . .
Carboxylic acids ; Salts or anhydrides thereof
A61K 47/14
. . .
Esters of carboxylic acids
{
e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens
}
Collapse
A61K 47/16
. .
containing nitrogen,
{
e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
}
Collapse
A61K 47/18
. . .
Amines ; Quaternary ammonium compounds,
{
e.g. amides, ureas
}
A61K 47/183
. . . .
{
Amino acids or aminosulphonic acids, e.g. glycine, EDTA, aspartame
}
A61K 47/186
. . . .
{
Quaternary ammonium compounds, e.g. benzalkonium chloride, cetrimide
}
A61K 47/20
. .
containing sulfur,
{
e.g. DMSO, docusate, sodium lauryl sulfate( A61K 47/183 , A61K 47/186 take precedence )
}
A61K 47/22
. .
Heterocyclic compounds,
{
e.g. ascorbic acid, tocopherol, pyrrolidones( A61K 47/183 , A61K 47/186 take precedence )
}
A61K 47/24
. .
containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur,
{
e.g. cyclomethicone, phospholipids
}
A61K 47/26
. .
Carbohydrates,
{
e.g. mono-, di-, oligosaccharides, nucleic acids, sugar alcohols, amino sugars; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters, glycyrrhizin( A61K 47/183 , A61K 47/186 take precedence )
}
A61K 47/28
. .
Steroids,
{
e.g. cholesterol, bile acids, glycyrrhetinic acid( A61K 47/183 , A61K 47/186 take precedence )
}
Collapse
A61K 47/30
.
Macromolecular compounds
A61K 47/32
. .
Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds,
{
e.g. carbomers, poly(meth)acrylates, polyvinyl pyrrolidone
}
A61K 47/34
. .
Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds,
{
e.g. polyesters, polyamino acids, polysiloxanes, copolymers of polyalkylene glycol or poloxamer( PEG or poloxamers A61K 47/10 )
}
NOTE
-
This group does not cover polyalkoxylated compounds, which are classified according to the derivatized compounds. The following list provides examples of such polyalkoxylated compounds together with their relevant group:
- POE alkyl ethers A61K 47/10
- PEG fatty acid esters A61K 47/14
- poloxamines A61K 47/18
- polysorbates A61K 47/26
- POE castor oil A61K 47/44

Collapse
A61K 47/36
. .
Polysaccharides ; Derivatives thereof,
{
e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar, pectin
}
A61K 47/38
. . .
Cellulose ; Derivatives thereof
A61K 47/40
. . .
Cyclodextrins ; Derivatives thereof
{
( cyclodextrin inclusion compounds A61K 47/48969 )
}
A61K 47/42
. .
Proteins ; Polypeptides ; Degradation products thereof ; Derivatives thereof
{
e.g. albumin, gelatin, zein( oligopeptides having up to 5 amino acids A61K 47/183 ; polyamino acids A61K 47/34 )
}
A61K 47/44
.
Oils, fats or waxes according to more than one of groups A61K 47/02 to A61K 47/42 ;
{
Natural or modified natural oils, fats or waxes, e.g.( polyethoxylated )castor oil, montan wax, ozokerite, lignite, shellac, rosin, beeswax, lanolin( synthetic glycerides, e.g. medium-chain triglycerides A61K 47/14 )
}
A61K 47/46
.
Ingredients of undetermined constitution or reaction products thereof,
{
e.g. skin, bone, milk, cotton fiber, eggshell, oxgall, plant extracts
}
Collapse
.
the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
Collapse
A61K 47/48007
. .
{
the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent
}
NOTE
-
The modifying agent being a macromolecular compound A61K47/48K, a peptide, protein or polyamino acid A61K47/48R, an antibody or immunoglobulin A61K47/48T

A61K 47/48015
. . .
{
the modifying agent being an inorganic compound; e.g. inorganic ion that being chemically complexed with the pharmacologically- or therapeutically-active agent( A61K 47/48161 takes precedence )
}
NOTE
-
Classic ion pairs of medicinal agents are not classified in A61K 47/48 but in A61K 31/00

Collapse
A61K 47/48023
. . .
{
the modifying agent being an organic compound( A61K 47/48161 takes precedence )
}
A61K 47/4803
. . . .
{
the modifying agent being an organic ion that forms an ion pair complex with the pharmacologically or therapeutically active agent.
}
A61K 47/48038
. . . .
{
the modifying agent being a carboxylic acid, e.g. a fatty acid or an amino acid
}
NOTE
-
When covalently linked to the pharmacologically or therapeutically-active agent, it can be via its carboxylic function or via another chemical function leaving the carboxylic function free

Collapse
A61K 47/48046
. . . .
{
the modifying agent being a lipid, e.g. a triglyceride; the modifying agent being a polyamine, e.g. spermine or spermidine
}
NOTE
-
Fatty acid conjugates are classified in A61K 47/48038 ;cholesterol conjugates are classified in A61K 47/48123

A61K 47/48053
. . . . .
{
the modifying agent being a phospholipid.
}
Collapse
A61K 47/48061
. . . .
{
the modifying agent being a heterocyclic compound( A61K 47/48153 takes precedence )
}
A61K 47/48069
. . . . .
{
the modifying agent being a heterocyclic compound which being a porphyrine or a porphyrine with an expanded ring system, e.g. texaphyrine
}
NOTE
-
Porphyrins used as photosensitizers in photodynamic therapy: see A61K 41/0071 or A61K 41/0076 ; Porphyrins used as photosensitizers in photodynamic therapy, the photosensitizer being considered as the therapeutically active part, and modified by another compound, e.g. polymer or an antibody, to be classified in A61K 41/0071 or A61K 41/0076 and according to the A61K 47/48 subgroup of the modifying agent; Porphyrins used as fluorescent diagnostic optical agents administered in vivo to be classified in A61K 49/0036

A61K 47/48076
. . . .
{
the modifying agent being a chelate, i.e. single central atom/ion sequestered by a polydentate ligand, e.g. Gd-DOTA or Zinc-amino acid chelate, or a chelate-forming compound, i.e. chelating group, e.g. DOTA or ethylenediamine, that being covalently/complexed to the pharmacologically- or therapeutically-active agent
}
NOTE
-
Paramagnetic chelates used in MRI and not linked to by further compound, e.g. polymer, peptide, protein, antibody, small molecules like sugars, are only classified in A61K 49/101 and subgroupes. Paramagnetic chelates used in MRI and conjugated to another compound, e.g. a polymer, a peptide, a protein, an antibody, a small molecule like a sugar, are classified in A61K 49/06 and subgroupes, and not A61K47/48K, if said other compound being not used as therapeutic agent, according to the nature of the modifying agent, and completed by A61K 49/085 . Radiolabelled chelates are classified in A61K 51/0474 and its subgroups, and in A61K 51/0497 , A61K 51/065 , A61K 51/088 or A61K 51/1093 if the chelate being linked to a further molecule, e.g. an organic compound, polymer, peptide, protein or polyamino acid, antibody

A61K 47/48084
. . . .
{
the modifying agent being a phosphate or phosphonate not being a phospholipid, e.g. bone-seeking
}
NOTE
-
nucleic acid carriers to be classified in A61K 47/48092

A61K 47/48092
. . . .
{
the modifying agent linked to the pharmacologically or therapeutically active agent being a sugar, nucleoside, nucleotide, nucleic acid
}
{
Note nucleic acids can be coding, non-coding, nucleic acid which being therapeutically-active or not, e.g.: oligonucleotides, DNA, RNA, siRNA, nucleic acid aptamers
}
Collapse
A61K 47/481
. . . .
{
the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds, e.g. a polymer of aspirin
}
{
Note a sugar, nucleoside, nucleotide, nucleic acid is classified in A61K 47/48092 ; a polymer of an active agent is not classified in A6K47/48K6
}
A61K 47/48107
. . . . .
{
one of the codrug's components being a vitamin, e.g. niacinamide( vitamin B3 ), cobalamin( vitamin B12 ), folate, vitamin A, retinoic acid
}
A61K 47/48115
. . . . .
{
one of the codrug's components being an antibiotic
}
A61K 47/48123
. . . .
{
the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone, bile acid
}
NOTE
-
- Cholesterol only classified here and not in A61K 47/48046 - Codrugs of pharmacologically active/therapeutically-active steroids are classified in this group and also in A61K 47/481

Collapse
A61K 47/4813
. . . .
{
pretargeting systems involving an organic compound, not being a peptide, protein or antibody, for targeting specific cells
}
NOTE
-
The concept of "pre-targeting" covers the administration of the modifying agent (which being an agent able to target specific cells in the body), and of the pharmacologically or therapeutically active agent (drug D) in several steps, their "binding" occurring at the in vivo targeted site. It involves administration in at least two steps, for example: (i) a conjugate T-A corresponding to a targeting agent able to target specific cells or receptors in the body (T) linked to a compound A, and (ii) a conjugate D-M corresponding to the drug linked to a modifying agent M able to target the compound A. The sequence involves e.g. the administration of T-A and then D-M. Between step (i) and step (ii), a further compound able to bind to A and M may also be administered, e.g. during a clearing step. Classification being made according to the nature of T in the subgroupes of A61K 47/4813 , A61K 47/48346 and A61K 47/48723 . In A61K 47/4813 and its subgroupes, T being an organic compound, not being a peptide, protein or antibody. Classification being also made according to the nature of organic compound T in the appropriate A61K 47/48023 subgroup. If T being a peptide, protein or antibody, classification being made in the corresponding A61K 47/48346 or A61K 47/48723 pretargeting class]

A61K 47/48138
. . . . .
{
ECTA, enzyme catalyzed therapeutic agent
}
NOTE
-
In the definition of A61K 47/4813 , an enzyme being used as group A, and being first targeted to specific cells via administration of the conjugate T-A. Then, the conjugate M-D which being a substrate for A being administered. The enzyme A being able to cleave the conjugate M-D, which can be e.g. a prodrug. The drug D being thus released through enzymatic cleavage at particular targeted cells

A61K 47/48146
. . . . .
{
the modifying agent being biotin
}
NOTE
-
In the definition of A61K 47/4813 , M and A form a pair of biotin and (strept)avidin, or derivatives of biotin and (strept)avidin

A61K 47/48153
. . . .
{
the modifying agent being a chemiluminescent acceptor
}
NOTE
-
A chemical reaction induces the cleavage of the pharmacologically or therapeutically active agent from the carrier while at the same time producing light. If the conjugate if cleaved through activation by light in vivo in order to release the drug, then the classification symbol being A61K41/00R. Dyes/luminescent agents for optical diagnostic imaging A61K49/00P; for photodynamic therapy A61K 41/0057

A61K 47/48161
. . . .
{
Redox delivery systems, e.g. dihydropyridine pyridinium salt redox systems
}
Collapse
A61K 47/48169
. .
{
the modifying agent being an organic macromolecular compound, i.e. an oligomeric, polymeric, dendrimeric molecule
}
NOTE
-
a peptide, protein, polyamino acid being classified in A61K 47/48238 and subgroupes; an antibody in A61K 47/48369 and subgroupes. In case of block copolymers, the different (large) blocks are classified in the appropriate A61K 47/48169 or A61K 47/48238 subgroups

Collapse
A61K 47/48176
. . .
{
the organic macromolecular compound has been obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly(meth)acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol
}
A61K 47/48184
. . . .
{
the macromolecular compound obtained by reactions only involving carbon-to-carbon unsaturated bonds being an ion exchange resin, e.g. polystyrene sulfonic acid resin
}
Collapse
A61K 47/48192
. . .
{
the organic macromolecular compound has been obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas, polyurethanes
}
A61K 47/482
. . . .
{
the macromolecule is/contains a polyester, e.g. PLGA, polylactide-co-glycolide
}
A61K 47/48207
. . . .
{
the macromolecule is/contains a polyamide, e.g. nylon( polyamino acids A61K 47/48238 )
}
A61K 47/48215
. . . .
{
the organic macromolecular compound being a polyoxyalkylene oligomer, polymer, dendrimer, e.g. PEG, PPG, PEO, polyglycerol
}
A61K 47/48223
. . . .
{
the macromolecule contains phosphorus in the main chain, e.g. poly-phosphazene
}
A61K 47/4823
. . .
{
the organic macromolecular compound being a polysaccharide or a derivative, e.g. starch, chitosan, chitin, cellulose, pectin, cyclodextrin with the pharmacologically active agent being covalently linked to the external surface of the ring structure, a bacterial polysaccharide or oligosaccharide antigen, a glycosaminoglycan
}
NOTE
-
if cyclodextrin being used to complex the drug, then the appropriate classification being A61K 47/48969 ; proteoglycans as modifying agents attached to the pharmacologically or therapeutically active agent are classified in the appropriate A61K 47/48238 subgroup

Collapse
A61K 47/48238
. .
{
the modifying agent being a protein, peptide, polyamino acid
}
NOTE
-
antibodies or immunoglobulins are classified in A61K 47/48369 subgroupes Special physical or galenic forms modified by covalent attachment or complexation of a protein, peptide or polyamino acid, are given the A61K 47/48238 class in addition to their corresponding A61K 47/48769 subgroup, e.g. a liposome modified on its surface by a peptide being classified in A61K 47/48815 and A61K 47/48238 , a PLGA nanoparticle modified on its surface by a peptide being classified in A61K 47/48915 and in A61K 47/48238 Peptidic linkers used to connect a drug and a modifying agent are classified in A61K 47/48338 , the modifying agent being also classified if it being defined

Collapse
A61K 47/48246
. . .
{
drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent
}
( peptidic linker are classified in A61K 47/48338 )
NOTE
-
The connection of the drug to the peptide, protein or polyamino acid can be by a direct covalent linkage or through a linker Fusion/chimeric proteins genetically produced, e.g. by recombinant DNA technology, are classified in C07K 2319/00 and subgroups, not in A61K 47/48246 and subgroups. A61K 47/48246 and its subgroups only cover the conjugates wherein a peptide or protein being the pharmacologically or therapeutically active agent has been linked to another peptide or protein being the modifying agent via chemical methods. In that latter example of a chemically-produced peptide or protein-peptide or protein conjugate, what being classified in A61K 47/48246 or in one of its subgroups being the peptide or protein used as modifying agent

A61K 47/48253
. . . .
{
the peptide, protein or polyamino acid in the drug conjugate being a branched, dendritic or hypercomb peptide
}
A61K 47/48261
. . . .
{
the peptide or protein in the drug conjugate being a toxin or a lectin, e.g. clostridial toxins or Pseudomonas exotoxin
}
A61K 47/48269
. . . .
{
the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors, interferons being the inactive part of the conjugate
}
NOTE
-
ligands of growth factors are not classified here

A61K 47/48276
. . . .
{
the peptide or protein in the drug conjugate being a receptor as such, e.g. CD4; a cell surface antigen( therefore not a peptide ligand targeting the antigen ); a cell surface determinant, i.e. a part of the surface of a cell
}
NOTE
-
a peptide targeting a receptor being not classified here

A61K 47/48284
. . . .
{
the peptide or protein in the drug conjugate being an albumin, e.g. HSA, BSA, ovalbumin, or a Keyhole Limpet Hemocyanin (KHL)
}
A61K 47/48292
. . . .
{
the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin, gelatin
}
A61K 47/483
. . . .
{
the peptide or protein in the drug conjugate being a transferrin, e.g. a lactoferrin or ovotransferrin
}
A61K 47/48307
. . . .
{
the peptide or protein in the drug conjugate being a haemoglobin
}
Collapse
A61K 47/48315
. . . .
{
the peptide or protein in the drug conjugate being a polycationic or polyanionic oligopeptide, polypeptide or polyamino acid, e.g. polylysine, polyarginine, polyglutamic acid, peptide TAT
}
A61K 47/48323
. . . . .
{
polyanionic oligopeptide, polypeptide or polyamino acid, used to complex nucleic acids being the therapeutic agent
}
A61K 47/4833
. . . .
{
the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
}
NOTE
-
Haptens, e.g. conjugate of morphine or nicotine and KLH inducing an immune response being classified in A61K 47/4833 and A61K 47/48284

A61K 47/48338
. . .
{
peptidic linker, binder, spacer, e.g. peptidic enzyme-labile linker
}
Collapse
A61K 47/48346
. . .
{
pretargeting systems involving a peptide or protein( not an antibody A61K 47/48723 )for targeting specific cells
}
NOTE
-
The concept of "pre-targeting" covers the administration of the modifying agent (which being an agent able to target specific cells in the body), and of the pharmacologically or therapeutically active agent (drug D) in several steps, their "binding" occurring at the in vivo targeted site. It involves administration in at least two steps, for example: (i) a conjugate T-A corresponding to a targeting agent T able to target specific cells or receptors in the body (T) linked to a compound A, and (ii) a conjugate D-M corresponding to the drug D linked to a modifying agent M, able to target the compound A. The sequence involves e.g. the administration of T-A and then D-M. Between step (i) and step (ii), a further compound able to bind to both A and M may also be administered (e.g. during a clearing step). Classification being made according to the nature of T in the subgroupes of A61K 47/4813 , A61K 47/48346 and A61K 47/48723 . In A61K 47/48346 and its subgroupes, T being a peptide or protein, not being a antibody. If M being biotin and A being a (strept)avidin or a derivative thereof, then A61K 47/48353 being used as classification symbol

A61K 47/48353
. . . .
[pretargeting system, clearing therapy or rescue therapy involving biotin-(strept)avidin systems]
NOTE
-
In this group, M and A in the definition of A61K 47/48346 can form a biotin/(strept)avidin system

A61K 47/48361
. . . .
{
Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy (GDEPT), VDEPT
}
NOTE
-
An enzyme being used as group A in the definition of A61K 47/4813 , and being first targeted to specific cells via administration of the conjugate T-A. Then, the conjugate M-D which being a substrate for A being administered. The enzyme A being able to cleave the conjugate M-D, which can be e.g. a prodrug. The drug D being thus released through enzymatic cleavage at particular targeted cells

Collapse
A61K 47/48369
. .
{
the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
}
Collapse
A61K 47/48376
. . .
{
drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
}
NOTE
-
The modifying part being an antibody or immunoglobulin bearing antigen-binding sites

Collapse
A61K 47/48384
. . . .
{
drug conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
}
NOTE
-
The modifying part being an antibody or immunoglobulin bearing at least one antigen-binding site. In A61K 47/48384 and its subgroupes, classification being made according to the nature of the drug, i.e. the pharmacologically or therapeutically active agent in the antibody conjugate. If the nature of the antibody in a specific conjugate being known, it being indicated with the corresponding A61K 47/48507 subgroup, in addition to the subgroup A61K 47/48384 characterizing the drug. If the conjugate comprises also a polymer or a polyamino acid, then the class A61K 47/48692 or A61K 47/487 being also given

A61K 47/48392
. . . . .
{
the drug being a vinca alkaloid
}
Collapse
A61K 47/484
. . . . .
{
the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
}
A61K 47/48407
. . . . . .
{
the drug being an antibiotic, e.g. one of the antitumor antibiotics: anthracyclins, adriamycin, doxorubicin, daunomycin
}
Collapse
A61K 47/48415
. . . . .
{
the drug being a protein or peptide, e.g. transferrin or bleomycin
}
A61K 47/48423
. . . . . .
{
the drug being a peptidic cytokine, e.g. an interleukin or interferon
}
A61K 47/4843
. . . . . .
{
the drug being an enzyme
}
Collapse
A61K 47/48438
. . . . . .
{
the drug being a toxin
}
Collapse
A61K 47/48446
. . . . . . .
{
the drug being a plant toxin
}
Collapse
A61K 47/48453
. . . . . . . .
{
the drug being a plant heterodimeric toxin; chains A or B containing toxins, e.g. abrin, modeccin
}
A61K 47/48461
. . . . . . . . .
{
the drug being ricin( double chain )
}
Collapse
A61K 47/48469
. . . . . . . .
{
the drug being a ribosomal inhibitory protein,( RIP-i or RIP-II ), e.g. Pap, gelonin, dianthin
}
A61K 47/48476
. . . . . . . . .
{
the drug being ricin A
}
A61K 47/48484
. . . . . . .
{
the drug being a bacterial toxin, e.g. diphteria toxin, Pseudomonas exotoxin A
}
A61K 47/48492
. . . . . . .
{
the drug being a fungal toxin, e.g. alpha sarcine, mitogillin, zinniol, restrictocin
}
A61K 47/485
. . . . . . .
{
the drug being a viral toxin
}
Collapse
A61K 47/48507
. . .
{
the modifying agent being a well defined antibody or immunoglobulin bearing at least one antigen-binding site
}
NOTE
-
According to the nature of the antibody, the appropriate A61K 47/48515 subgroup being given. If the pharmacologically or therapeutically active agent in the antibody conjugate being known, the appropriate A61K 47/48384 subgroup being also given

Collapse
A61K 47/48515
. . . .
{
not used; see subgroups
}
Collapse
A61K 47/48523
. . . . .
{
the antibody being against material from viruses
}
A61K 47/4853
. . . . . .
{
the antibody being targeting a RNA virus
}
A61K 47/48538
. . . . .
{
the antibody being targeting a material from animals or humans.
}
A61K 47/48546
. . . . .
{
the antibody being targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
}
A61K 47/48553
. . . . .
{
the antibody being targeting an hormone, or an hormone-releasing or -inhibiting factor
}
A61K 47/48561
. . . . .
{
the antibody being targeting a receptor, a cell surface antigen, a cell surface determinant
}
Collapse
A61K 47/48569
. . . . .
{
the antibody being targeting a determinant of a tumour cell
}
A61K 47/48576
. . . . . .
{
the tumour determinant being carcino-embryonic antigen
}
A61K 47/48584
. . . . . .
{
the tumour determinant being from breast cancer cell
}
A61K 47/48592
. . . . . .
{
the tumour determinant being from lung cancer cell
}
A61K 47/486
. . . . . .
{
the tumour determinant being from liver or pancreas cancer cell
}
A61K 47/48607
. . . . . .
{
the tumour determinant being from kidney or bladder cancer cell
}
A61K 47/48615
. . . . . .
{
the tumour determinant being from stomach or intestines cancer cell
}
A61K 47/48623
. . . . . .
{
the tumour determinant being from skin, nerves or brain cancer cell
}
A61K 47/4863